Dermatitis
MONDO:0002406An inflammatory process affecting the skin. Signs include red rash, itching, and blister formation. Representative examples are contact dermatitis, atopic dermatitis, and seborrheic dermatitis.
Also known as: inflammation of skin, inflammation of the skin, inflammation of zone of skin, inflammatory skin disease, skin inflammation, zone of skin inflammation
1411 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsSub-types
Broader categories
Showing the 400 most recently updated of 472 trials in this tab.
-
New ear oil shows promise against fungal infections
⭐️ CURE ⭐️ CompletedThis study tested whether miconazole oil can cure fungal ear infections (otomycosis). 112 adults with ear fungus received either the active oil or a placebo for 14 days. Neither patients nor doctors knew who got the real treatment. After two weeks, doctors checked if the infectio…
Phase: PHASE3 • Sponsor: Hill Dermaceuticals, Inc. • Aim: ⭐️ CURE ⭐️
Last updated Jun 27, 2026 12:31 UTC
-
Scalp ringworm showdown: which antifungal works best for kids?
⭐️ CURE ⭐️ CompletedThis study compared two oral antifungal medications—itraconazole and terbinafine—for treating scalp ringworm (tinea capitis) in 164 children aged 1 to 13 years. The goal was to see which drug more effectively clears the fungal infection, confirmed by lab tests. Both treatments ai…
Phase: NA • Sponsor: Muhammad Aamir Latif • Aim: ⭐️ CURE ⭐️
Last updated Jun 27, 2026 08:00 UTC
-
New drug aims to tame severe eczema in kids and teens
Disease control CompletedThis study tests an experimental drug called SHR-1819 in children and adolescents aged 6 to 17 with moderate-to-severe atopic dermatitis (a type of eczema). The main goal is to check the drug's safety and how the body processes it. Researchers will also look at changes in skin-re…
Phase: PHASE1, PHASE2 • Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New drug 611 shows promise for kids with severe eczema
Disease control CompletedThis study tests a new antibody drug called 611 in 124 Chinese children and adolescents aged 6 to 18 with moderate to severe atopic dermatitis (eczema). The drug targets a protein involved in inflammation. The main goals are to check safety and how the drug moves through the body…
Phase: PHASE1, PHASE2 • Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Heartburn drug could ease painful sun sensitivity
Disease control CompletedThis Phase 2 trial tested whether oral cimetidine (Tagamet), a common heartburn drug, can reduce light sensitivity in people with erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP). These genetic conditions cause severe pain from sunlight exposure. The study en…
Phase: PHASE2 • Sponsor: Amy K. Dickey, M.D. • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New psoriasis drug shows promise in chinese trial
Disease control CompletedThis phase 3 study tested the drug bimekizumab in 133 Chinese adults with moderate to severe plaque psoriasis. Participants received either bimekizumab or a placebo for 16 weeks. The main goals were to see if bimekizumab could clear at least 90% of psoriasis (PASI90) and achieve …
Phase: PHASE3 • Sponsor: UCB Biopharma SRL • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New shot shows promise for tough eczema in major trial
Disease control CompletedThis phase 3 study tested a drug called rocatinlimab in 726 adults with moderate-to-severe atopic dermatitis (eczema) that wasn't well controlled by creams. Participants received either the drug or a placebo as a shot under the skin for 24 weeks. The main goals were to see if the…
Phase: PHASE3 • Sponsor: Amgen • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New biologic drug shows promise for eczema in early trial
Disease control CompletedThis early-phase trial tested a new biologic drug called UCB1381 in 109 people, first in healthy volunteers and then in those with moderate to severe atopic dermatitis (eczema). The goal was to check safety and see if it improves eczema symptoms. Participants received either the …
Phase: PHASE1, PHASE2 • Sponsor: UCB Biopharma SRL • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New shot could tame severe eczema in kids
Disease control CompletedThis study tested a drug called nemolizumab in 109 children aged 2 to 11 with moderate-to-severe eczema. The drug is given as a shot under the skin every 4 weeks for a year. Researchers measured how the drug moves through the body, its safety, and whether it improves eczema sympt…
Phase: PHASE2 • Sponsor: Galderma R&D • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New study targets psoriasis treatment gap in skin of color patients
Disease control CompletedThis completed Phase 3 trial tested the drug guselkumab (Tremfya) in 211 people with skin of color who have moderate-to-severe plaque psoriasis or scalp psoriasis. Participants received either guselkumab or a placebo injection. The study measured how well the drug cleared skin le…
Phase: PHASE3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New serum combo takes on stubborn toenail fungus
Disease control CompletedThis completed study tested two topical serums for treating toenail fungus (onychomycosis). 44 adults with mild to moderate infection applied one or both serums daily for 112 days. Researchers measured the change in healthy nail area using photos. The goal was to see if using bot…
Phase: NA • Sponsor: Swiss Footcare Laboratories - Poderm Professional • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Psoriasis drug guselkumab under microscope in new immune study
Disease control CompletedThis study is testing how the drug guselkumab affects the immune system in people with two types of psoriasis: plaque and guttate. Twenty-five adults will receive guselkumab injections over 44 weeks. Researchers will measure changes in immune cells in the skin to understand how t…
Phase: PHASE4 • Sponsor: University of California, San Francisco • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New drug BGB-45035 tested for eczema and itchy skin condition
Disease control CompletedThis study tested a new drug called BGB-45035 for the first time in humans. It looked at safety in healthy volunteers and then in people with autoimmune skin diseases like atopic dermatitis (eczema) and prurigo nodularis (a condition causing intensely itchy bumps). The goal was t…
Phase: PHASE1 • Sponsor: BeiGene • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New combo therapy targets both psoriasis and obesity in major trial
Disease control CompletedThis study tests whether adding a weight-loss drug (tirzepatide) to a standard psoriasis treatment (ixekizumab) helps people with moderate-to-severe plaque psoriasis who are also overweight or obese. About 250 adults will receive either ixekizumab alone or both drugs together for…
Phase: PHASE3 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New pill shows promise for severe eczema sufferers
Disease control CompletedThis study tested a daily pill called upadacitinib in 912 teens and adults with moderate to severe eczema (atopic dermatitis) that was not well controlled with creams. Participants received either the study drug or a placebo for 16 weeks. The main goals were to see if the drug co…
Phase: PHASE3 • Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Could an asthma drug tame this brutal blistering disease?
Disease control CompletedThis study tested whether dupilumab, a drug already used for asthma and eczema, can help people with bullous pemphigoid, a painful blistering skin condition. 106 adults received either dupilumab or a placebo, plus standard steroid treatment. The main goal was to see if more peopl…
Phase: PHASE2, PHASE3 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Herbal ointment shows promise for eczema relief
Disease control CompletedThis completed trial tested a herbal ointment made from Syzygium formosum leaves in 90 people with mild to moderate atopic dermatitis (eczema). The ointment was compared to standard moisturizers to see if it was safe and effective. The study measured skin severity, water loss, an…
Phase: NA • Sponsor: VinUniversity • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Could a single pill cure scabies? new study tests three doses
Disease control CompletedThis study tested whether a single dose of an oral drug called moxidectin can cure scabies, a skin condition caused by tiny mites. 200 adults with confirmed scabies received either 8 mg, 16 mg, or 32 mg of moxidectin or a placebo. The main goal was to see if the drug could comple…
Phase: PHASE2 • Sponsor: Medicines Development for Global Health • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Lamp vs laser: which light works best for vitiligo?
Disease control CompletedThis study compared two types of ultraviolet light treatments—an excimer lamp and an excimer laser—for repigmenting white patches caused by vitiligo. Adults with at least two matching patches of vitiligo received both treatments on different patches twice a week for 12 weeks. The…
Phase: PHASE3 • Sponsor: Centre Hospitalier Universitaire de Nice • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Acne Treatment's Oil-Reducing power put to the test
Disease control CompletedThis study investigates whether clascoterone cream 1%, an FDA-approved acne medication, works by reducing sebum (skin oil) production. Researchers will measure forehead oil levels and changes in skin bacteria in 40 participants aged 12 and older with mild to moderate acne. The go…
Phase: PHASE4 • Sponsor: Sun Pharmaceutical Industries Limited • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Can a fatty acid cream heal damaged skin? new trial tests it
Disease control CompletedThis completed trial tested a cream made from a fatty acid called tripalmitoleoylglycerol in 46 adults with chronic dermatitis. Participants applied the cream or a placebo daily for 30 days. Researchers measured skin barrier function and symptom scores to see if the cream improve…
Phase: NA • Sponsor: Shenzhen People's Hospital • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Could a drug plus light therapy reverse vitiligo? new trial tests the combo
Disease control CompletedThis phase 2 trial tested whether adding the oral drug baricitinib to phototherapy (light treatment) helps restore skin color in adults with progressive vitiligo. 49 participants received either baricitinib plus phototherapy or a placebo plus phototherapy for 36 weeks. The main g…
Phase: PHASE2 • Sponsor: University Hospital, Bordeaux • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Teens with rare swelling disorder get new drug tested
Disease control CompletedThis study looked at how a new oral medication (sebetralstat) works in the bodies of 11 teenagers aged 12 to 17 with hereditary angioedema (HAE) types I or II. The goal was to measure drug levels and timing in the blood. All participants were already in a larger HAE trial. The st…
Phase: PHASE3 • Sponsor: KalVista Pharmaceuticals, Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New ointment shows promise for restoring skin color in vitiligo
Disease control CompletedThis phase 2 trial tested an ointment called MH004 in 156 people with non-segmental vitiligo, a condition that causes white patches on the skin. Participants applied the ointment to affected areas once or twice daily for 24 weeks. The study measured how much skin color returned, …
Phase: PHASE2 • Sponsor: Minghui Pharmaceutical (Hangzhou) Ltd • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
Eczema drug upadacitinib under Real-World safety check in china
Disease control CompletedThis study looks at how safe and effective upadacitinib is for Chinese adolescents and adults with moderate to severe atopic dermatitis (eczema). About 200 participants will take the drug as prescribed by their doctor and be followed for up to 24 months. The goal is to track seri…
Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New pill shows promise for controlling rare swelling disorder
Disease control CompletedThis study looked at the long-term safety of an oral medication called KVD900 for treating swelling attacks in people with hereditary angioedema (HAE) types I or II. The trial enrolled 145 adolescents and adults who had already completed a previous study. Participants took KVD900…
Phase: PHASE3 • Sponsor: KalVista Pharmaceuticals, Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New shot could stop painful swelling attacks in kids
Disease control CompletedThis study tested a drug called Garadacimab in 22 children aged 2 to 11 with hereditary angioedema, a condition that causes sudden, painful swelling. The drug is given as a shot under the skin to prevent attacks. The study looked at safety and how well it works. It has already be…
Phase: PHASE3 • Sponsor: CSL Behring • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Eczema drug nemolizumab put to the vaccine test
Disease control CompletedThis study looked at whether nemolizumab, a drug for moderate-to-severe eczema, interferes with the body's ability to respond to tetanus and meningococcal vaccines. 242 adults and teens with eczema received either nemolizumab or a placebo, plus the vaccines. The goal was to see i…
Phase: PHASE2 • Sponsor: Galderma R&D • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New injection shows promise for long-term prevention of rare swelling disorder
Disease control CompletedThis study tested the long-term safety and effectiveness of garadacimab, a monthly injection, for preventing attacks of hereditary angioedema (HAE) — a rare condition causing severe swelling. 171 people aged 12 and older who had frequent HAE attacks took part. The goal was to see…
Phase: PHASE3 • Sponsor: CSL Behring • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Eczema drug shows promise in repairing skin barrier
Disease control CompletedThis study looked at how the drug abrocitinib affects the skin barrier in 20 adults with moderate to severe atopic dermatitis (eczema). Researchers measured water loss from the skin and changes in skin-related genes at 2 and 12 weeks. The goal was to see if the treatment helps re…
Sponsor: Prof. Dr. Stephan Weidinger • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New pill shows promise for Long-Term psoriasis relief
Disease control CompletedThis study tested a new oral medication, JNJ-77242113, for long-term control of moderate-to-severe plaque psoriasis. 227 adults who completed a previous 16-week study continued treatment for up to 36 more weeks. The goal was to see how well the drug kept skin clear over time.
Phase: PHASE2 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New eczema pill shows promise in large trial
Disease control CompletedThis study tested an oral medication called upadacitinib in 912 teenagers and adults with moderate to severe eczema (atopic dermatitis) who needed stronger treatment. Participants received either the drug or a placebo for 16 weeks. The main goals were to see if the drug could sig…
Phase: PHASE3 • Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New drug shows promise for rare muscle disease
Disease control CompletedThis study tested an experimental drug called daxdilimab in 12 adults with dermatomyositis or anti-synthetase myositis that wasn't well controlled by standard treatments. The goal was to see if the drug could reduce disease activity and skin symptoms, and help lower steroid use o…
Phase: PHASE2 • Sponsor: Amgen • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
Eczema drug dupilumab shows promise in skin of color patients
Disease control CompletedThis study tested the drug dupilumab (Dupixent) in 124 adolescents and adults with darker skin tones who have moderate-to-severe eczema. Participants received injections every two weeks for 24 weeks. The goal was to see if the drug safely improves skin symptoms and quality of lif…
Phase: PHASE4 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Can a common arthritis drug help stop vitiligo from spreading?
Disease control CompletedThis phase 2 trial tested whether adding methotrexate (a drug used for arthritis) to standard UVB light therapy works better than light therapy alone for adults with active, spreading vitiligo. Thirty-two participants were randomly assigned to receive either methotrexate pills pl…
Phase: PHASE2 • Sponsor: University Hospital, Bordeaux • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
Molecular map may guide treatment for mysterious inflammatory illnesses
Disease control CompletedThis study tested whether analyzing a patient's DNA and RNA could help doctors pick the right drug for inflammatory diseases that don't fit standard categories. 32 adults with at least two affected organs (including skin) received one of six targeted therapies based on their mole…
Phase: PHASE2 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
New pill could stop hives from scratching or cold
Disease control CompletedThis phase 2a trial tested an oral drug called EVO756 in 30 adults with chronic inducible urticaria, a condition where physical triggers like scratching or cold cause hives. The study aimed to see if the drug is safe and can reduce wheals. Results are not yet available.
Phase: PHASE2 • Sponsor: Evommune, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
Could vitamin d help clear acne? new trial tests the idea
Disease control CompletedThis completed trial tested whether adding vitamin D supplements to standard acne treatment (azithromycin and a topical retinoid) improves acne more than standard treatment alone. Fifty-eight people aged 13 to 40 with acne vulgaris took part. The main goal was to see if the combi…
Phase: NA • Sponsor: HITEC-Institute of Medical Sciences • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New psoriasis drug shows promise for teens in early trial
Disease control CompletedThis study tested two doses of bimekizumab, a drug that targets inflammation, in 41 adolescents aged 12 to 17 with moderate to severe plaque psoriasis. The main goals were to measure how the drug behaves in the body and to check its safety. Researchers also looked at how well it …
Phase: PHASE2 • Sponsor: UCB Biopharma SRL • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
Rituximab shows promise for long-term control of rare blistering skin disease
Disease control CompletedThis study followed 80 patients with pemphigus, a rare autoimmune disease that causes painful blisters on skin and mucous membranes. Researchers wanted to see how safe and effective rituximab (a drug that targets certain immune cells) is over the long term, compared to standard h…
Phase: PHASE3 • Sponsor: University Hospital, Rouen • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New eczema drug shows promise in 2-Year extension trial
Disease control CompletedThis study looked at the long-term safety and effectiveness of lebrikizumab for adults and teens with moderate-to-severe atopic dermatitis (eczema). Participants who completed a previous year-long study could join this 2-year extension. The main goal was to see how many people st…
Phase: PHASE3 • Sponsor: Almirall, S.A. • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New light therapy takes on stubborn toenail fungus
Disease control CompletedThis study tested two treatments for toenail fungus in 27 Asian adults: a light-activated dye (methylene blue photodynamic therapy) and a medicated nail polish (amorolfine). The goal was to see which worked better and was safer. Participants received either the light treatment or…
Phase: NA • Sponsor: Chulalongkorn University • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New pill could ease rare muscle disease
Disease control CompletedThis study tested an oral drug called GLPG3667 (Cadefrecitinib) in 40 adults with dermatomyositis, a rare disease causing muscle weakness and skin rash. Participants took the drug or a placebo daily for 24 weeks to see if it improves symptoms. The trial is complete, and results w…
Phase: PHASE2 • Sponsor: Lakefront Biotherapeutics NV • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
Real-world dupixent study tracks eczema improvement in 305 canadians
Disease control CompletedThis study followed 305 Canadian adults and children (ages 6+) with moderate-to-severe eczema who were prescribed Dupixent as part of their routine care. Researchers measured how many patients achieved at least a 75% reduction in eczema severity after 6, 12, and 18 months. The go…
Sponsor: Sanofi • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New drug trial aims to tame severe eczema in kids
Disease control CompletedThis study tested a drug called tralokinumab in 28 children aged 6 to 12 with moderate-to-severe eczema. The goal was to see how the drug moves through the body and if it is safe. Children received injections over several weeks and used moisturizers daily. The trial is complete, …
Phase: PHASE2 • Sponsor: LEO Pharma • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Cheap drugs may tame severe sun allergy
Disease control CompletedThis completed study tested two older, low-cost drugs—methotrexate and azathioprine—against chronic actinic dermatitis, a painful skin reaction to sunlight. Fifty adults were randomly assigned to one drug for 24 weeks. Researchers tracked eczema severity and safety. The goal was …
Phase: EARLY_PHASE1 • Sponsor: Pak Emirates Military Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Could an antibody fight both psoriasis and heart disease?
Disease control CompletedThis phase 2 trial tested a drug called orticumab in 77 adults with moderate-to-severe psoriasis who also had cardiometabolic risks (like obesity and high cholesterol). The goal was to see if orticumab could safely reduce skin plaques and inflammation linked to heart disease. Par…
Phase: PHASE2 • Sponsor: Abcentra • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
New psoriasis drug matches leading biologic in Head-to-Head trial
Disease control CompletedThis phase 3 trial tested whether a new biologic called CMAB015 works as well as secukinumab (Cosentyx) for moderate-to-severe plaque psoriasis. 336 adults received either drug for up to 48 weeks. The main goal was to see if at least 75% of skin symptoms improved by week 12. The …
Phase: PHASE3 • Sponsor: Taizhou Mabtech Pharmaceutical Co.,Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
New drug navenibart aims to tame hereditary swelling attacks
Disease control CompletedThis early trial tested a new drug called navenibart in 29 people with hereditary angioedema (HAE), a condition that causes sudden, painful swelling attacks. Participants received one or two doses of the drug to check its safety and how well it might reduce attacks. The study is …
Phase: PHASE1, PHASE2 • Sponsor: Astria Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
New drug shows promise for controlling rare swelling disorder
Disease control CompletedThis study tested the long-term safety and effectiveness of donidalorsen, an injectable drug, in 20 people with hereditary angioedema (HAE), a condition that causes sudden, painful swelling attacks. Participants received different doses over 64 weeks. The main goal was to check f…
Phase: PHASE2 • Sponsor: Ionis Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
Could a common arthritis drug tame rare immune disease Flare-Ups?
Disease control CompletedThis study tested the drug tofacitinib (Xeljanz) in 10 adults with chronic granulomatous disease (CGD) who had ongoing inflammation in the gut, skin, or lungs. Participants took the pill daily for 3 months to see if it was safe and could help control symptoms. The goal was to fin…
Phase: PHASE1, PHASE2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
Promising drug tackles rare eye disease that leads to blindness
Disease control CompletedThis early-phase trial tested the drug rituximab in 3 people with ocular cicatricial pemphigoid, a rare autoimmune disease that causes scarring in the eye and can lead to blindness. The goal was to see if the drug could stop further scarring when standard treatments had failed. T…
Phase: PHASE1, PHASE2 • Sponsor: University of Alabama at Birmingham • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Light shines on fungus: new device tackles toenail infection
Disease control CompletedThis study tested a light therapy device called ToeFX for mild to moderate toenail fungus. 126 people with fungal infection in one big toenail used the device. Researchers measured new clear nail growth after 12 months to see if the treatment worked and was safe.
Phase: NA • Sponsor: ToeFX Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Sun-Powered clothing could ease psoriasis and hair loss
Disease control CompletedThis study tested special clothing made with Lumiton yarn that captures sunlight and turns it into red and near-infrared light, aiming to improve skin conditions like psoriasis, alopecia areata, and polymorphous light eruption. Eighteen adults with mild-to-severe forms of these c…
Phase: NA • Sponsor: Wake Forest University Health Sciences • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
New psoriasis pill shows promise in early trial
Disease control CompletedThis study tested an oral tablet called JNJ-77242113 in 90 adults with moderate-to-severe plaque psoriasis. Participants were randomly assigned to receive the drug or a placebo for 16 weeks. The main goal was to see if the drug could improve psoriasis symptoms by at least 75% com…
Phase: PHASE2 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
New psoriasis pill zasocitinib takes on deucravacitinib in Head-to-Head trial
Disease control CompletedThis completed Phase 3 trial tested whether the experimental drug zasocitinib works better than the approved drug deucravacitinib for moderate-to-severe plaque psoriasis. Over 600 participants took one tablet and one capsule daily for 16 weeks. The main goal was to see how many a…
Phase: PHASE3 • Sponsor: Takeda • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
New hope for Tough-to-Treat psoriasis: guselkumab targets sensitive areas
Disease control CompletedThis completed phase 3 trial tested the drug guselkumab against a placebo in 338 adults with moderate plaque psoriasis covering only 2-15% of their body but including special sites like the scalp, face, or genitals. The goal was to see if guselkumab could clear or nearly clear ps…
Phase: PHASE3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
New eczema ointment shows promise in early trial
Disease control CompletedThis study tested an ointment called RSS0393 in 168 adults with mild to moderate atopic dermatitis (eczema). Participants used different strengths of the ointment or a placebo for a set period. The goal was to see if the ointment could clear or nearly clear the skin rash. Results…
Phase: PHASE2 • Sponsor: Reistone Biopharma Company Limited • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
New shot shows promise for tough eczema in early trial
Disease control CompletedThis study tested a new drug called SHR-1819 in 158 adults with moderate to severe atopic dermatitis (a type of eczema). Participants received one of three doses of the drug or a placebo. The main goal was to see if the drug could reduce eczema severity by at least 75% after 16 w…
Phase: PHASE2 • Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
Skyrizi under the microscope: Real-World safety data on over 2,300 patients
Disease control CompletedThis study tracked over 2,300 adults in Korea who were prescribed Skyrizi (risankizumab) for moderate to severe plaque psoriasis or psoriatic arthritis. Researchers monitored side effects and symptom changes for 52 weeks during routine doctor visits. The goal was to confirm the d…
Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
New study tests easier treatment for blistering skin disease
Disease control CompletedThis study tested two ways to treat bullous pemphigoid, a severe blistering skin condition. One group used strong steroid creams for 9 months, while the other used steroids plus methotrexate for 4 weeks, then methotrexate alone for 8 months. The goal was to see if the combination…
Phase: PHASE3 • Sponsor: University Hospital, Montpellier • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Shampoo shows promise for scalp psoriasis in small study
Disease control CompletedThis study tested Daxxin Psoriasis Shampoo in 41 adults with moderate scalp psoriasis. Participants used the shampoo 3 to 7 times a week for 6 weeks. The goal was to see if it reduced scalp redness, thickness, and scaling, and improved quality of life. Results showed most people …
Phase: NA • Sponsor: Daxxin AB • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Heavier psoriasis patients may need a stronger dose of brodalumab
Disease control CompletedThis study tested whether a higher dose of the drug brodalumab works better than the standard dose for people with moderate-to-severe plaque psoriasis who weigh at least 120 kg. The trial involved 385 adults and lasted 52 weeks. The main goal was to see if more patients on the hi…
Phase: PHASE4 • Sponsor: LEO Pharma • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Can diet and exercise boost a psoriasis Drug's power?
Disease control CompletedThis study looked at 781 adults with moderate-to-severe plaque psoriasis and metabolic syndrome (a cluster of conditions like high blood pressure and obesity). Researchers wanted to see if adding a lifestyle intervention (diet and exercise) to the drug Secukinumab (Cosentyx) impr…
Phase: PHASE4 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New antibody drug shows promise for vitiligo in early trial
Disease control CompletedThis phase 2a trial tested an experimental drug called AMG 714 in 60 adults with vitiligo, a condition that causes white patches on the skin. The drug works by blocking a protein called IL-15, which may play a role in the disease. Participants received either AMG 714 or a placebo…
Phase: PHASE2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New drug combo shows promise for rare childhood muscle disease
Disease control CompletedThis study tested the drug baricitinib, given with steroids, in 16 children aged 3-18 with newly diagnosed juvenile dermatomyositis, a rare disease causing muscle weakness and skin rashes. The goal was to see if baricitinib works better than the standard treatment (methotrexate p…
Phase: PHASE2 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New hope for psoriasis patients who Didn't respond to leading therapies
Disease control CompletedThis study tested a drug called bimekizumab in 60 adults with moderate-to-severe plaque psoriasis who had not improved with other similar treatments. The drug works by blocking certain inflammatory substances in the body to reduce skin redness, scaling, and thickness. The main go…
Phase: PHASE4 • Sponsor: Icahn School of Medicine at Mount Sinai • Aim: Disease control
Last updated Jun 27, 2026 12:10 UTC
-
Eczema cream showdown: steroid vs Non-Steroid in kids
Disease control CompletedThis study tested two creams for mild to moderate eczema in 40 children aged 1-12. One cream was a steroid (fluticasone), the other a non-steroid (crisaborole). Both were applied twice daily for 6 weeks, then twice weekly for 12 weeks if the skin improved a lot. Both treatments w…
Phase: NA • Sponsor: Noura Abdelmoneim Mohammed Elseessy • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
Ear drop showdown: which works better for fungal infections?
Disease control CompletedThis study compared two ear drop treatments for otomycosis, a fungal infection of the outer ear that causes itching, discharge, and blockage. Sixty patients were randomly assigned to receive either clotrimazole or 2% salicylic acid drops three times daily for two weeks. The main …
Phase: NA • Sponsor: Mayo Hospital Lahore • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
New psoriasis drug shows promise in major trial
Disease control CompletedThis study tested a new drug called bimekizumab in 567 adults with moderate to severe plaque psoriasis. Participants received either bimekizumab, a placebo, or another active drug. The main goal was to see how well bimekizumab cleared skin lesions after 16 weeks. Results showed s…
Phase: PHASE3 • Sponsor: UCB Biopharma SRL • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
New drug bimekizumab shows promise in clearing psoriasis in phase 3 trial
Disease control CompletedThis phase 3 study tested bimekizumab, a drug given by injection, against a placebo in 435 adults with moderate to severe plaque psoriasis. The main goal was to see how many people achieved at least 90% skin clearing after 16 weeks. The trial also looked at complete clearing and …
Phase: PHASE3 • Sponsor: UCB Biopharma SRL • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Psoriasis showdown: which drug clears skin faster?
Disease control CompletedThis study compares two already-approved drugs, risankizumab (injection) and deucravacitinib (pill), for adults with moderate plaque psoriasis. About 393 participants who haven't used biologics before will receive one of the treatments for up to 44 weeks. The goal is to see which…
Phase: PHASE4 • Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
One-Dose hope for blistering skin disease?
Disease control CompletedThis study tested whether a single cycle of rituximab can control bullous pemphigoid, a severe blistering skin condition. Eighteen adults with steroid-dependent or relapsing disease were enrolled. Researchers checked disease control weekly for a month and then monthly for two yea…
Phase: PHASE3 • Sponsor: University Hospital, Rouen • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
New psoriasis drug bimekizumab outperforms secukinumab in major trial
Disease control CompletedThis Phase 3 trial tested bimekizumab against secukinumab and placebo in 743 adults with moderate to severe plaque psoriasis. The main goal was to see how many patients achieved complete skin clearance (PASI100) at 16 weeks. Bimekizumab showed superior results compared to secukin…
Phase: PHASE3 • Sponsor: UCB Biopharma SRL • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New shot shows promise for tough psoriasis cases
Disease control CompletedThis Phase 3 trial tested netakimab, a biologic drug given as a shot, against a placebo in 202 Chinese adults with moderate-to-severe plaque psoriasis. The main goal was to see if netakimab could improve skin symptoms by at least 75% (PASI75) or achieve clear/almost clear skin (s…
Phase: PHASE3 • Sponsor: SPH-BIOCAD (HK) Limited • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New psoriasis drug shows promise in Head-to-Head trial
Disease control CompletedThis study tested a new medicine called bimekizumab against an existing drug (adalimumab) in 478 adults with moderate to severe plaque psoriasis. The goal was to see if bimekizumab could clear more skin at 16 weeks. Participants received either bimekizumab or adalimumab, and then…
Phase: PHASE3 • Sponsor: UCB Biopharma SRL • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
Psoriasis drug bimekizumab shows promise in Long-Term safety trial
Disease control CompletedThis study looked at the long-term safety and tolerability of bimekizumab in over 1,300 adults with moderate to severe plaque psoriasis. Participants who completed earlier studies received bimekizumab injections over several years. The main goal was to track side effects and see …
Phase: PHASE3 • Sponsor: UCB Biopharma SRL • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New psoriasis pill shows promise in major trial
Disease control CompletedThis study tested a new daily medicine called ESK-001 in 862 adults with moderate to severe plaque psoriasis. The goal was to see if it reduces psoriasis severity and is safe, comparing it to a placebo and an existing drug (apremilast). Participants took the medicine for 24 weeks…
Phase: PHASE3 • Sponsor: Alumis Inc • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
New psoriasis pill shows promise in large trial
Disease control CompletedThis study tested whether a new daily pill, ESK-001, can safely reduce psoriasis severity in adults with moderate to severe plaque psoriasis. Over 900 participants took either ESK-001, a placebo (dummy pill), or an approved psoriasis drug (apremilast) for 24 weeks. Researchers me…
Phase: PHASE3 • Sponsor: Alumis Inc • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
Eczema breakthrough? postbiotic cream may keep Kids' skin calm
Disease control CompletedThis study tested whether a moisturizer containing postbiotic Saccharomyces and Lactobacillus can reduce the risk of eczema returning in children aged 0-6 years who are in remission. 98 children used either the special emollient or a standard one for 12 weeks. The goal was to see…
Phase: NA • Sponsor: Children's Hospital of Fudan University • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
One pill could change the fight against sleeping sickness in kids
Disease control CompletedThis study tested a single dose of the oral drug acoziborole in 35 children aged 1 to 14 with sleeping sickness (g-HAT). The goal was to see how the drug works in the body and if it is safe and effective. This simpler treatment could help control the disease in remote areas where…
Phase: PHASE2, PHASE3 • Sponsor: Drugs for Neglected Diseases • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New psoriasis ointment shows promise in large chinese trial
Disease control CompletedThis study tested a new ointment (LEO 90100) against a standard one (Daivobet) for stable plaque psoriasis in 604 Chinese adults. Participants applied the treatment for 4 weeks. The goal was to see if the new ointment could clear or nearly clear psoriasis patches better than the …
Phase: PHASE3 • Sponsor: LEO Pharma • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New gel shows promise for ugly toenail fungus
Disease control CompletedThis study tested a special gel, CGB-400, on 15 adults with toenail fungus. The goal was to see if the gel could clear the fungus and make the nails look better. Participants applied the gel for 12 weeks, with follow-up visits to check progress.
Sponsor: CAGE Bio Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Real-world study shows lanadelumab keeps HAE attacks at bay for many patients
Disease control CompletedThis study followed 48 people with hereditary angioedema (HAE) in Poland who were taking lanadelumab as part of a national drug program. Researchers tracked how many participants remained attack-free over 24 months, how many attacks still needed rescue treatment, and the severity…
Sponsor: Takeda • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
New shot shows promise for tough eczema in phase 3 trial
Disease control CompletedThis study tested a biologic drug called SIM0718 in 259 adults and teens with moderate to severe atopic dermatitis (eczema) that did not respond well to creams. Participants received either the drug or a placebo every two weeks for 16 weeks. The goal was to see if the drug could …
Phase: PHASE3 • Sponsor: Simcere Pharmaceutical Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
New eczema cream shows promise in tiny trial
Disease control CompletedThis completed Phase 2 trial tested a new ointment called CGB-500 (containing tofacitinib) against an approved cream (ruxolitinib) for atopic dermatitis, a type of eczema. Only 3 people aged 12 and older took part, applying both treatments to different skin areas twice daily for …
Phase: PHASE2 • Sponsor: CAGE Bio Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
Can a pill plus light therapy restore skin color in vitiligo?
Disease control CompletedThis study tested whether the drug apremilast, taken as a pill twice daily, combined with narrowband UVB light therapy can help restore skin color in people with widespread vitiligo. 80 adults with stable or slowly progressing vitiligo covering at least 10% of their body took par…
Phase: PHASE2 • Sponsor: Centre Hospitalier Universitaire de Nice • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New drug bimekizumab shows promise for psoriasis in early trial
Disease control CompletedThis Phase 2 trial tested the drug bimekizumab in 49 adults with moderate to severe plaque psoriasis. Participants received either bimekizumab or a placebo, and researchers measured how well the drug cleared skin and how long it stayed in the body. The goal was to see if bimekizu…
Phase: PHASE2 • Sponsor: UCB Biopharma SRL • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New antibody shows promise for blistering skin disease
Disease control CompletedThis phase 2 trial tested avdoralimab, an antibody that blocks a specific immune signal, added to standard steroid cream for bullous pemphigoid—a severe blistering skin condition mostly affecting older adults. Fifteen participants received the combination to see if it leads to co…
Phase: PHASE2 • Sponsor: Centre Hospitalier Universitaire de Nice • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Eczema patients learn to Self-Inject in new study
Disease control CompletedThis study tested whether teenagers and adults with moderate-to-severe eczema (atopic dermatitis) could successfully give themselves injections of the drug rocatinlimab at home using special devices. The main goal was to see how many full doses were self-administered correctly up…
Phase: PHASE3 • Sponsor: Amgen • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Can a cholesterol drug help stop vitiligo?
Disease control CompletedThis study tested whether adding the cholesterol drug atorvastatin to standard UVB light therapy works better than UVB alone for active vitiligo. 28 adults with active, non-segmental vitiligo took part. The main goal was to see if the combination reduced the amount of skin color …
Phase: PHASE2 • Sponsor: Centre Hospitalier Universitaire de Nice • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Laser treatment could offer new hope for chronic skin condition
Disease control CompletedThis study tested a new dual laser treatment for vulvar lichen sclerosus, a chronic skin condition causing discomfort. 66 participants were randomly assigned to receive either laser therapy or standard steroid cream. The goal was to see if the laser works as well as the cream, po…
Phase: NA • Sponsor: Prof. Dr. Volker Viereck • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Cream shows promise for genital vitiligo in early trial
Disease control CompletedThis phase 2 trial tested a cream called ruxolitinib (Opzelura) on 49 people with nonsegmental vitiligo affecting the genitals. Participants applied the cream twice daily for up to 48 weeks to see if it made the white patches less noticeable. The study measured success based on p…
Phase: PHASE2 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jun 27, 2026 11:04 UTC
-
New ankle machine could help athletes recover from sprains
Disease control CompletedThis study tested a new ankle training machine in 14 athletes with chronic ankle instability. The machine allows for multi-directional strengthening while sitting. Researchers compared it to standard resistance band training over six weeks, measuring muscle strength, balance, and…
Phase: NA • Sponsor: China Medical University Hospital • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
Psoriasis breakthrough: lower drug doses may work just as well
Disease control CompletedThis study tested whether psoriasis patients who are stable on biologic drugs (IL17 or IL23 inhibitors) can safely reduce their dose without their skin condition getting worse. Researchers enrolled 244 adults with plaque psoriasis who had been on a normal dose for at least 6 mont…
Phase: PHASE4 • Sponsor: Radboud University Medical Center • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
New eczema drug shows promise in Late-Stage trial
Disease control CompletedThis Phase 3 study tests amlitelimab, an injected drug, in 589 people aged 12 and older with moderate-to-severe atopic dermatitis (eczema) that hasn't responded well to topical treatments. The goal is to see if amlitelimab can clear or nearly clear the skin and reduce eczema seve…
Phase: PHASE3 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
New drug shows promise for rare, severe psoriasis
Disease control CompletedThis Phase 3 trial tested a drug called imsidolimab in 45 adults with generalized pustular psoriasis (GPP), a rare and severe skin condition that causes painful pustules. Participants received either a single intravenous dose of imsidolimab (750 mg or 300 mg) or a placebo. The ma…
Phase: PHASE3 • Sponsor: Vanda Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
New eczema drug shows promise in Mid-Stage trial
Disease control CompletedThis study tested a new drug, AK120, in 450 adults with moderate to severe atopic dermatitis (eczema). The main goal was to check for side effects and see how well the drug works. Researchers measured changes in eczema severity using standard skin scores.
Phase: PHASE2 • Sponsor: Akeso • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
New pill shows promise for tough eczema in small study
Disease control CompletedThis study tested an experimental oral drug called ATI-2138 in 14 adults with moderate to severe atopic dermatitis (eczema). Participants took the pill twice daily for 12 weeks. Researchers tracked safety, side effects, and skin improvement using standard eczema scores. The goal …
Phase: PHASE2 • Sponsor: Aclaris Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
Generic acne gel put to the test in large trial
Disease control CompletedThis completed Phase 1 trial compared a generic tretinoin gel (0.04%) to the brand-name RETIN-A MICRO for treating acne vulgaris. Over 1,000 participants aged 12 to 40 with mild to moderate acne applied the gel daily for 12 weeks. The goal was to see if the generic version works …
Phase: PHASE1 • Sponsor: Sun Pharmaceutical Industries, Inc. • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
New hope for kids with severe psoriasis: QLETLI shows promise
Disease control CompletedThis study looked at whether QLETLI, a biosimilar of adalimumab, is safe and effective for children and teens aged 4 to 17 with severe plaque psoriasis. A total of 80 participants were followed for 24 weeks. The main goal was to see how much their psoriasis symptoms improved, mea…
Sponsor: Bio-Thera Solutions • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
New pill could tame stubborn hives when antihistamines fail
Disease control CompletedThis phase 2 trial tested an oral drug called povorcitinib in 136 adults with chronic spontaneous urticaria (hives and itching lasting months) that standard antihistamines couldn't control. Participants took either povorcitinib or a placebo for 12 weeks to see if the drug reduced…
Phase: PHASE2 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Dose debate: which rituximab regimen works best for rare blistering disease?
Disease control CompletedThis study looked back at 275 pemphigus patients to see how different doses of rituximab affected disease control and relapse. Pemphigus is a rare autoimmune disease that causes painful blisters on skin and mucous membranes. Researchers tracked outcomes like flare-ups, side effec…
Sponsor: Ruijin Hospital • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New eczema drug shows promise for people with darker skin
Disease control CompletedThis study tested the drug lebrikizumab in 90 adults and teens with moderate-to-severe eczema who have skin of color. The goal was to see if the drug is safe and helps clear skin. Participants received injections over 24 weeks, and doctors measured improvement using a standard ec…
Phase: PHASE3 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Eczema drug SHR-1819 passes extended safety test in 79 patients
Disease control CompletedThis study looked at the long-term safety of the drug SHR-1819 in 79 adults with moderate to severe eczema who had already taken part in earlier studies of the same drug. Researchers tracked side effects and how well the drug controlled the disease over time. The goal was to see …
Phase: PHASE2 • Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:11 UTC
-
Eyelid wipes zap Mite-Caused eye inflammation in new study
Disease control CompletedThis study tested whether cleaning the eyelids with wipes containing chlorhexidine can treat blepharitis caused by Demodex mites. 106 adults with the condition used the wipes twice daily for four weeks. Researchers measured mite counts and eyelash debris before and after treatmen…
Phase: PHASE4 • Sponsor: Instituto de Oftalmología Fundación Conde de Valenciana • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
Psoriasis drug tildrakizumab tested in everyday practice
Disease control CompletedThis observational study followed 331 adults with moderate-to-severe plaque psoriasis who were treated with tildrakizumab (Ilumetri) as part of their routine care. Researchers tracked how much the skin cleared and how quality of life improved over up to two years. The goal was to…
Sponsor: Almirall, S.A. • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
New hope for eczema sufferers with painful itchy nodules?
Disease control CompletedThis study tested the drug upadacitinib in people with moderate to severe atopic dermatitis (eczema) who also have prurigo nodularis, a condition causing intense itching and hard bumps. The goal was to see if the drug reduces itching and improves skin. The study was observational…
Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
Cream showdown: which antifungal works best for jock itch?
Disease control CompletedThis study tested two antifungal creams—oxiconazole and clotrimazole—against each other in 386 adults with jock itch (tinea cruris). The goal was to see which one better relieved itching and redness. Both creams are already used for fungal skin infections, so this trial aimed to …
Phase: EARLY_PHASE1 • Sponsor: Hayat Abad Medical Complex, Peshawar • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
Can a daily pill bring back skin color? new trial tests ritlecitinib for vitiligo
Disease control CompletedThis Phase 3 study tested ritlecitinib, an oral drug, in 607 adults and adolescents with nonsegmental vitiligo (a type of white patches on the skin). Participants took either the drug or a placebo daily for 52 weeks. The main goals were to see if the drug could improve skin color…
Phase: PHASE3 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
New hope for psoriasis sufferers: drug targets Hard-to-Treat areas
Disease control CompletedThis study tested the drug risankizumab (Skyrizi) in 214 adults with moderate to severe genital or scalp psoriasis. Participants received either the drug or a placebo for 16 weeks, then all received the drug. The goal was to see if it could clear or nearly clear the skin in these…
Phase: PHASE4 • Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
Chromium picolinate shows promise for teen skin condition linked to insulin resistance
Disease control CompletedThis study tested whether taking chromium picolinate daily for 24 weeks could reduce the severity of acanthosis nigricans (dark, thick skin patches) and improve insulin resistance in adolescents aged 12 to 18. Researchers compared the supplement to a placebo in 90 participants. T…
Phase: NA • Sponsor: Uruk University • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
New hope for eczema patients when first treatment fails
Disease control CompletedThis study tested a drug called lebrikizumab in 86 adults and teens with moderate-to-severe eczema who had already tried dupilumab. The goal was to see if lebrikizumab could safely improve their skin condition. Researchers measured how many participants achieved at least a 75% im…
Phase: PHASE3 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
New combo therapy may beat stubborn fungal infections
Disease control CompletedThis study tested whether adding isotretinoin (a retinoid that changes skin oil and growth) to the standard antifungal itraconazole works better than itraconazole alone for adults with resistant Trichophyton fungal skin infections. 148 adults aged 18-65 with confirmed infection w…
Phase: NA • Sponsor: Multan Medical And Dental College • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
New yeast infection pill could stop repeat episodes
Disease control CompletedThis study tested a new oral medication, oteseconazole, to see if it can prevent recurrent yeast infections in women who have had at least three infections in the past year. Over 400 participants took either the study drug or a placebo for 12 weeks after an initial treatment, and…
Phase: PHASE3 • Sponsor: Mycovia Pharmaceuticals Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
New pill may keep yeast infections away for good
Disease control CompletedThis study tested a new oral medication, oteseconazole, to see if it can prevent recurrent yeast infections in women who have had at least three infections in the past year. Participants first received standard treatment for their current infection, then took either oteseconazole…
Phase: PHASE3 • Sponsor: Mycovia Pharmaceuticals Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
Shining a light on vaginal infections: new device tested
Disease control CompletedThis study tested a device that uses UVA and blue light to treat bacterial vaginosis and yeast infections. 38 women received one or two light treatments. Researchers checked if symptoms improved and if the vaginal microbiome became healthier. The goal is to find an alternative to…
Phase: NA • Sponsor: UVISA Health ApS • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
New psoriasis pill shows promise in Mid-Stage trial
Disease control CompletedThis study tested an experimental drug called JNJ-77242113 in 255 adults with moderate-to-severe plaque psoriasis. The goal was to see if different doses could clear at least 75% of skin symptoms after 16 weeks compared to a placebo. Participants had psoriasis for at least 6 mont…
Phase: PHASE2 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
New eczema drug shows promise in Mid-Stage trial
Disease control CompletedThis study tested a new medicine called LEO 138559 (Temtokibart) in 262 adults with moderate-to-severe atopic dermatitis (eczema). Participants received one of four doses or a placebo as injections under the skin for 16 weeks. The goal was to see how well the drug reduces eczema …
Phase: PHASE2 • Sponsor: LEO Pharma • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
Massive korean study confirms Upadacitinib's Real-World safety
Disease control CompletedThis study looked at how safe and effective upadacitinib is for Korean patients with rheumatoid arthritis, atopic dermatitis, ankylosing spondylitis, or psoriatic arthritis. Over 2,300 adults took the drug as prescribed by their doctor and were followed for about 28 weeks. Resear…
Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
New hope for stubborn hand eczema: drug targets inflammation from within
Disease control CompletedThis study tested a daily pill called abrocitinib in 82 adults with moderate to severe chronic hand eczema that did not get better with steroid creams. The goal was to see if the drug could reduce skin redness, scaling, and other symptoms. Researchers also checked for side effect…
Phase: PHASE2 • Sponsor: Innovaderm Research Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
New psoriasis drug SHR-1139 enters first human trials
Disease control CompletedThis early-stage trial tests a new drug called SHR-1139 in healthy volunteers and people with moderate-to-severe plaque psoriasis. The main goal is to check safety and how the body handles the drug. A total of 64 participants will receive either the drug or a placebo, with doses …
Phase: PHASE1 • Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Could a diabetes drug boost psoriasis treatment?
Disease control CompletedThis study tested whether adding metformin, a common diabetes drug, to cyclosporine works better for psoriasis than cyclosporine alone. Thirty-two adults with moderate to severe psoriasis took part. Researchers measured skin improvement, body surface area affected, and quality of…
Phase: PHASE1 • Sponsor: Cairo University • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Vitiligo showdown: new drug vs. old combo in Head-to-Head trial
Disease control CompletedThis study tested whether a newer cream (ruxolitinib) works better alone or when combined with two older creams (tacrolimus and corticosteroids) for vitiligo. 120 adults with limited vitiligo (less than 10% of body affected) were split into three groups and treated for 24 weeks. …
Phase: PHASE4 • Sponsor: Dow University of Health Sciences • Aim: Disease control
Last updated Jun 27, 2026 08:14 UTC
-
Can psoriasis patients skip more shots? new trial tests extended guselkumab dosing
Disease control CompletedThis study tested whether people with moderate-to-severe plaque psoriasis who achieve complete skin clearance after 20 weeks of guselkumab (Tremfya) can maintain that control with injections every 16 weeks instead of every 8 weeks. About 880 participants were enrolled, and the ma…
Phase: PHASE3 • Sponsor: Janssen-Cilag International NV • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Real-World data reveals how HAE drugs perform in chinese patients
Disease control CompletedThis study reviewed medical records of 115 Chinese people with hereditary angioedema (HAE) to see how well two approved drugs work in real life. One drug, lanadelumab, is used to prevent attacks, and the other, icatibant, treats sudden attacks. Researchers measured attack rates a…
Sponsor: Takeda • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
New eczema pill shows promise in long-term control for teens and adults
Disease control CompletedThis study tested the safety and effectiveness of abrocitinib, a daily pill, for people aged 12 and older with moderate to severe eczema. Participants took either 100 mg or 200 mg of abrocitinib for up to 92 weeks, with some continuing until the drug became commercially available…
Phase: PHASE3 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
New acne drug shows promise for skin of color patients
Disease control CompletedThis study tested the acne cream Winlevi in 10 people with darker skin tones (Fitzpatrick types IV, V, VI). The goal was to see how well it cleared or nearly cleared acne after 16 weeks. Acne is very common, but there is little research focused on skin of color, so this study hel…
Phase: PHASE4 • Sponsor: Sun Pharmaceutical Industries Limited • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
New eczema drug shows promise for teens in major trial
Disease control CompletedThis study tested a drug called rocatinlimab in 532 teenagers with moderate-to-severe eczema that didn't improve with standard creams. The goal was to see if the drug could clear skin and reduce itching over 24 to 52 weeks. Participants received either the drug or a placebo, and …
Phase: PHASE3 • Sponsor: Amgen • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
New eczema drug 611 shows promise in large chinese trial
Disease control CompletedThis Phase 3 trial tested a new drug called 611 in 519 Chinese adults with moderate-to-severe atopic dermatitis (eczema). 611 is an antibody that blocks a key driver of allergic inflammation. The study compared 611 injections to a placebo over 16 weeks, measuring skin clearance a…
Phase: PHASE3 • Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
Higher dose offers new hope for psoriasis patients who stopped responding to standard therapy
Disease control CompletedThis study tested a higher dose (10 mg/kg every 8 weeks) of the drug TA-650 in 51 adults with psoriasis who had initially improved on the standard dose of Remicade but later lost that benefit. The goal was to see if the increased dose could again reduce skin symptoms. Participant…
Phase: PHASE3 • Sponsor: Tanabe Pharma Corporation • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
New shot offers hope for stubborn hand eczema
Disease control CompletedThis study tested a drug called tralokinumab for people with moderate-to-severe atopic hand eczema that hasn't improved with standard treatments. 235 adults received either the drug or a placebo every two weeks for 16 weeks, then everyone got the drug for another 16 weeks. The go…
Phase: PHASE3 • Sponsor: LEO Pharma • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
Light-Activated gel shows promise for psoriasis in early trial
Disease control CompletedThis study tested a gel called SGX302, which is activated by visible light, on 15 people with mild-to-moderate plaque psoriasis. The goal was to see if it could clear or nearly clear skin lesions over 18 weeks. The treatment is applied to the skin and then exposed to light, aimin…
Phase: PHASE2 • Sponsor: Soligenix • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
New hope for psoriasis: oral drug shows promise in chinese trial
Disease control CompletedThis study tested the drug apremilast (Otezla) in 203 Chinese adults with moderate to severe plaque psoriasis. Participants took either apremilast or a placebo pill twice daily for 16 weeks. The main goal was to see if more people on apremilast achieved at least a 75% improvement…
Phase: PHASE3 • Sponsor: Amgen • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
Could a common cough medicine ingredient soothe eczema?
Disease control CompletedThis study tested whether a cream containing N-acetyl cysteine (NAC) could improve mild-to-moderate eczema better than plain cold cream. One hundred people with eczema used either the NAC cream or a placebo cold cream. Researchers measured changes in skin bacteria (Staph) and ecz…
Phase: NA • Sponsor: Cairo University • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
New pill could tame tough eczema
Disease control CompletedThis Phase 2 trial tested an experimental oral drug called SCD-044 in 250 adults with moderate to severe atopic dermatitis (eczema). Participants received one of three doses of SCD-044 or a placebo for 16 weeks. The main goal was to see if the drug could reduce eczema severity by…
Phase: PHASE2 • Sponsor: Sun Pharmaceutical Industries Limited • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
New hope for kids with psoriasis: cosentyx® shows promise in chinese study
Disease control CompletedThis study followed 42 children aged 6 to 17 with moderate to severe plaque psoriasis in China who were treated with Cosentyx® (secukinumab) for up to 52 weeks. The goal was to see how safe and effective the drug is in real-world settings. Researchers tracked side effects and mea…
Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
Ear infection showdown: boric acid vs. povidone iodine
Disease control CompletedThis study tested two common treatments for fungal ear infections: boric acid and povidone iodine. Sixty patients were treated with one of the two solutions applied directly to the ear canal. The goal was to see which one clears the infection better and reduces symptoms like pain…
Phase: NA • Sponsor: Mansoura University • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
Kids with psoriasis get extended relief in new drug study
Disease control CompletedThis study looked at the long-term safety and effects of the drug apremilast in 160 children aged 6 to 17 with moderate to severe plaque psoriasis. Participants who had already completed one year of treatment could continue taking the drug for up to 208 weeks (about 4 years). The…
Phase: PHASE3 • Sponsor: Amgen • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
Acne drug dose showdown: which roaccutane dose works best?
Disease control CompletedThis completed trial tested two different cumulative doses of the acne drug Roaccutane (120 mg/kg vs 150 mg/kg) in 91 people with severe cystic acne. Researchers measured how well each dose reduced acne lesions and severity, and tracked whether acne returned within a year. The go…
Phase: PHASE4 • Sponsor: Premier Specialists, Australia • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
Eczema cream shows promise for Long-Term use in large trial
Disease control CompletedThis study looked at the long-term safety of a cream called roflumilast for people with mild to moderate eczema (atopic dermatitis). Over 1,200 participants, ages 2 and up, applied the cream once daily for up to 52 weeks. The main goal was to track any side effects, with secondar…
Phase: PHASE3 • Sponsor: Arcutis Biotherapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
Could a common parasite drug help young kids with scabies?
Disease control CompletedThis study tested the safety and effectiveness of oral ivermectin for treating scabies in children weighing 5 to less than 15 kilograms. 240 children participated, receiving either ivermectin, a standard permethrin cream, or a placebo. The goal is to see if ivermectin can be a sa…
Phase: PHASE2 • Sponsor: University of Oxford • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
New ivermectin minitablets could treat scabies in infants and toddlers
Disease control CompletedThis completed Phase 2 trial tested oral ivermectin minitablets in 13 children aged 3 months and older weighing 5 to less than 15 kilograms who had scabies. The study aimed to check the safety, how the drug works in the body, and how well it treats the infection. Results will hel…
Phase: PHASE2 • Sponsor: University of Oxford • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
New psoriasis drug shows promise in large trial
Disease control CompletedThis Phase 3 trial tested a new drug called JS005 in 747 adults with moderate-to-severe plaque psoriasis. JS005 is an antibody that blocks IL-17A, a protein that drives inflammation in psoriasis. The study compared JS005 to a placebo to see if it could improve skin clearance, mea…
Phase: PHASE3 • Sponsor: Shanghai Junshi Bioscience Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
Generic psoriasis cream could offer cheaper alternative to VTAMA®
Disease control CompletedThis study tested whether a generic tapinarof cream works as well as the brand-name VTAMA® cream for adults with plaque psoriasis. 560 participants used either the generic cream, the brand-name cream, or a placebo for 12 weeks. The goal was to see if the generic version is equall…
Phase: PHASE3 • Sponsor: Teva Pharmaceuticals USA • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
New pill may beat old drug for stubborn eczema
Disease control CompletedThis study tested whether baricitinib (a newer pill) works better than azathioprine (an older pill) for adults with moderate-to-severe eczema. Both groups also used steroid creams. The goal was to see which combination reduces skin redness, thickness, and itching more effectively…
Phase: NA • Sponsor: Mazandaran University of Medical Sciences • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
New shot could stop chronic hives when antihistamines fail
Disease control CompletedThis Phase 2 trial tested a new injectable drug called LP-003 in 202 adults with chronic spontaneous urticaria (long-lasting hives and itching) that standard antihistamines couldn't control. The study compared LP-003 to a placebo and to an existing drug (omalizumab) to see if it …
Phase: PHASE2 • Sponsor: Longbio Pharma • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
New pill D-2570 shows promise against stubborn psoriasis in early trial
Disease control CompletedThis phase 2 clinical trial tested an experimental oral drug called D-2570 in 161 adults with moderate-to-severe plaque psoriasis. Participants were randomly assigned to one of three doses of D-2570 or a placebo for 12 weeks. The main goal was to see how many people achieved at l…
Phase: PHASE2 • Sponsor: InventisBio Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
New shot could tame teen eczema
Disease control CompletedThis study tested a drug called rocatinlimab in 187 teenagers aged 12 to 17 with moderate-to-severe eczema that didn't respond well to standard creams. The goal was to see if the drug is safe and tolerable over 52 weeks. Participants received regular injections, and researchers t…
Phase: PHASE3 • Sponsor: Amgen • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Could HIV drugs help clear psoriasis? tiny study explores the idea
Disease control CompletedThis small study tested whether a short course of HIV drugs (emtricitabine and tenofovir) could reduce inflammation in people with plaque psoriasis. Only 8 people took part, and the main goal was to see changes in certain markers in skin biopsies. The study is complete, but resul…
Phase: NA • Sponsor: Centre Hospitalier Universitaire de Nīmes • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Could a common arthritis drug ease skin woes in down syndrome?
Disease control CompletedThis study tested whether tofacitinib, a drug already approved for arthritis, is safe and helpful for immune-related skin conditions in people with Down syndrome. 47 adolescents and adults with Down syndrome and skin issues like eczema or psoriasis took the drug. Researchers chec…
Phase: PHASE2 • Sponsor: University of Colorado, Denver • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Sugar and sound waves: a new acne treatment?
Disease control CompletedThis completed study tested whether applying a dextrose (sugar) gel with ultrasound, called phonophoresis, can improve mild to moderate acne. 115 people aged 18 to 30 with acne took part. The goal was to see if this approach reduces acne lesions and severity.
Phase: NA • Sponsor: MTI University • Aim: Disease control
Last updated Jun 27, 2026 08:02 UTC
-
Laser or cream? new study tests best treatment for lichen sclerosus
Disease control CompletedThis study tested two treatments for lichen sclerosus, a chronic skin condition causing itching and pain. 246 women received either a non-ablative CO2 laser treatment or a steroid cream (clobetasol) for three months. The goal was to see which works better at reducing symptoms lik…
Phase: PHASE3 • Sponsor: Ruhr University of Bochum • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
Massive study tests everyday supplements against autoimmune disease and aching knees
Disease control CompletedThis large study looked at whether taking daily vitamin D or fish oil supplements could lower the risk of developing autoimmune diseases (like rheumatoid arthritis), reduce signs of inflammation in the blood, and ease chronic knee pain. Over 25,000 adults without prior cancer or …
Phase: NA • Sponsor: Brigham and Women's Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
New drug shot shows promise for tough eczema in large trial
Disease control CompletedThis study tested a new drug called amlitelimab, given as a shot under the skin, for people aged 12 and older with moderate-to-severe atopic dermatitis (eczema) that wasn't controlled by creams. The trial included 643 participants and compared amlitelimab to a placebo, while ever…
Phase: PHASE3 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
New drug may offer safer relief for painful mouth condition
Disease control CompletedThis study tested two drugs, apremilast and methotrexate, added to standard steroid treatment for oral lichen planus, a chronic inflammatory mouth condition causing pain and sores. 64 adults with moderate to severe disease who didn't respond to topical steroids took either apremi…
Phase: PHASE4 • Sponsor: All India Institute of Medical Sciences, Bhubaneswar • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
Which antibiotic wins for skin infections? study pits doxycycline against TMP-SMX
Disease control CompletedThis study compared two common antibiotics, doxycycline and TMP-SMX, for treating uncomplicated skin infections like boils and cellulitis. 269 people aged 9 to 85 took one of the drugs for 7 days. Researchers checked if the infection cleared up early, at the end of treatment, and…
Phase: PHASE2 • Sponsor: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
New acne pill tested for Long-Term safety in 240 patients
Disease control CompletedThis study tested the long-term safety of a daily pill called ASC40 (Denifanstat) in 240 people with moderate to severe acne who had already completed a previous phase 3 trial. Participants took the drug once daily for up to 40 weeks, with regular blood tests and checkups to moni…
Phase: PHASE3 • Sponsor: Ascletis Pharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
New drug shows promise for rare blistering skin condition
Disease control CompletedThis early study tested a drug called bertilimumab in 11 adults aged 60 and older with newly diagnosed bullous pemphigoid, a condition that causes painful blisters. The main goals were to check safety and see if the drug helps control the disease. While results may show some bene…
Phase: PHASE2 • Sponsor: Alexion Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
Psoriasis drug shows promise for heart health in small study
Disease control CompletedThis study looked at whether tildrakizumab, a drug already approved for psoriasis, can improve blood flow to the heart in people with moderate-to-severe psoriasis. 36 adults took the drug for 6 months, and researchers measured heart function using special scans. The goal was to s…
Phase: PHASE4 • Sponsor: Marcelo F. Di Carli, MD, FACC • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
New hope for kids with stubborn hives: dupixent studied
Disease control CompletedThis study tested the drug dupilumab (Dupixent) in 15 children aged 2 to 12 who have chronic spontaneous urticaria (CSU), also known as long-lasting hives, that didn't get better with antihistamines. The main goals were to check how the drug behaves in the body and to see if it's…
Phase: PHASE3 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
Ancient herbal mix tested for stubborn eczema in small trial
Disease control CompletedThis completed Phase 3 trial tested a Chinese herbal formula called Xiao-Xian-Gui-Fu-Tang in 19 people aged 6 to 30 with moderate to severe atopic dermatitis (eczema). Participants took the herbal blend or a placebo for several weeks. Researchers measured changes in eczema severi…
Phase: PHASE3 • Sponsor: Taipei Veterans General Hospital, Taiwan • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
New eczema drug shows promise in major trial
Disease control CompletedThis study tested a new medicine called rocatinlimab, given as an injection, for adults with moderate-to-severe eczema that wasn't well controlled with standard creams. About 746 participants received either the study drug or a placebo, along with topical treatments. The goal was…
Phase: PHASE3 • Sponsor: Amgen • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
New shot shows promise for tough eczema cases
Disease control CompletedThis study tested a new medicine called amlitelimab, given as a shot under the skin, for people aged 12 and older with moderate-to-severe eczema that didn't get better with creams or other treatments. The goal was to see if it can clear or nearly clear the skin and reduce itching…
Phase: PHASE3 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
Blood filter shows promise for severe psoriasis in early trial
Disease control CompletedThis completed pilot study tested whether filtering inflammatory molecules from the blood using a device called Efferon CT can help people with severe psoriasis. Sixty adults with moderate to severe plaque psoriasis received the treatment, which involves circulating blood through…
Phase: NA • Sponsor: Efferon JSC • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
One shot wonder? new antibiotic trial for Kids' skin infections
Disease control CompletedThis study tested a single dose of the antibiotic oritavancin in 118 children aged 3 months to 12 years with acute bacterial skin infections. The goal was to see if it is safe and tolerable. Researchers also looked at how the drug works in the body and whether it cures the infect…
Phase: PHASE2 • Sponsor: Melinta Therapeutics, LLC • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
New psoriasis pill shows promise in early trial
Disease control CompletedThis phase 2 trial tested an experimental drug called BMS-986322 in 109 adults with moderate-to-severe plaque psoriasis. Participants received either the drug or a placebo for 12 weeks. The main goal was to see if the drug could significantly reduce psoriasis skin symptoms (measu…
Phase: PHASE2 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
New eczema drug shows promise in large trial
Disease control CompletedThis study tested a new medication called rocatinlimab for adults with moderate-to-severe eczema (atopic dermatitis). About 769 people took part to see if the drug can clear skin and reduce itching better than a placebo. The goal is to provide a new treatment option for those who…
Phase: PHASE3 • Sponsor: Amgen • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
New pill could stop swelling attacks in hereditary angioedema
Disease control CompletedThis study tested an oral medication called deucrictibant for quickly treating attacks of hereditary angioedema (HAE), a condition causing sudden, painful swelling. The trial involved 134 adolescents and adults with HAE types 1, 2, or 3. Participants took either the drug or a pla…
Phase: PHASE3 • Sponsor: Pharvaris Netherlands B.V. • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
New psoriasis pill TAK-279 shows promise in large trial
Disease control CompletedThis study tested an experimental oral drug called TAK-279 in 1,108 adults with moderate-to-severe plaque psoriasis. Participants received either TAK-279, a placebo, or an approved psoriasis drug (apremilast) for up to 69 weeks. The main goal was to see if TAK-279 could clear or …
Phase: PHASE3 • Sponsor: Takeda • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
Chemical peels show promise for acne and dark spots in new study
Disease control CompletedThis study tested three types of chemical peels—50% glycolic acid, 30% salicylic acid, and modified Jessner's—on 90 adults with mild to moderate facial acne and post-acne dark spots. Participants received one type of peel, and doctors measured improvements in acne severity and pi…
Phase: NA • Sponsor: Nahla Maher Mahmoud Mahran • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
Experimental drug shows promise for rare muscle diseases
Disease control CompletedThis study tested the long-term safety and effectiveness of a drug called KZR-616 in 18 adults with active polymyositis or dermatomyositis, rare diseases that cause muscle inflammation and weakness. Participants who completed an earlier study received weekly injections of KZR-616…
Phase: PHASE2 • Sponsor: Kezar Life Sciences, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
New psoriasis drug shows promise in early trial
Disease control CompletedThis phase 2a study tested an experimental drug called ASKP1240 in 60 adults with moderate to severe plaque psoriasis. Participants received either the drug or a placebo intravenously. The main goals were to check safety, how the drug moves through the body, and early signs of ef…
Phase: PHASE2 • Sponsor: Astellas Pharma Global Development, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
New daily pill could stop painful swelling attacks in rare disease
Disease control CompletedThis study tested an oral drug called BCX4161 to prevent attacks of hereditary angioedema (HAE), a condition that causes sudden, painful swelling. Over 12 weeks, 110 adults with HAE took either a low dose, high dose, or placebo pill. Researchers tracked how many swelling attacks …
Phase: PHASE2, PHASE3 • Sponsor: BioCryst Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
Psoriasis drug risankizumab tested against rivals in large Real-World study
Disease control CompletedThis completed study followed 2759 adults with moderate to severe plaque psoriasis to see how well risankizumab works compared to other commonly used biologic drugs. Researchers measured skin clearance and how long patients stayed on treatment. The goal was to understand real-wor…
Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
Experimental drug KZR-616 tested for rare muscle disorders
Disease control CompletedThis Phase 2 trial tested a drug called KZR-616 (zetomipzomib) in 25 adults with active polymyositis or dermatomyositis, two rare diseases that cause muscle inflammation and weakness. Participants received either the drug or a placebo for 16 weeks, then switched to the other trea…
Phase: PHASE2 • Sponsor: Kezar Life Sciences, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
New pill shows promise for psoriasis in early trial
Disease control CompletedThis study tested a new oral medication, SAR441566, in 221 adults with moderate to severe plaque psoriasis. Participants received either the drug or a placebo for 12 weeks. The main goal was to see if the drug could reduce psoriasis severity by at least 75%. Results will help det…
Phase: PHASE2 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
New shot could tame stubborn hives that antihistamines Can't stop
Disease control CompletedThis Phase 2 study tested a drug called barzolvolimab (CDX-0159) in 196 adults with chronic inducible urticaria—hives triggered by cold or scratching—that persist despite antihistamines. Participants received either the drug or a placebo as a shot under the skin. The main goal wa…
Phase: PHASE2 • Sponsor: Celldex Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
New eczema drug shows promise in Long-Term safety trial
Disease control CompletedThis study tested the long-term safety and effectiveness of lebrikizumab, a drug for moderate-to-severe atopic dermatitis (eczema). Over 1,100 participants who had already taken the drug in earlier studies were followed for up to 33 months. The goal was to see how well the drug c…
Phase: PHASE3 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
New pill shows promise for stubborn scalp psoriasis
Disease control CompletedThis study tested an oral medication called deucravacitinib against a placebo in 154 adults with moderate-to-severe scalp psoriasis. The main goal was to see if more people achieved clear or almost clear scalp skin after 16 weeks of treatment. This is a disease-control study, mea…
Phase: PHASE4 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
New psoriasis pill shows promise in large trial
Disease control CompletedThis Phase 3 study tested an experimental oral drug called TAK-279 in 693 adults with moderate-to-severe plaque psoriasis. Participants received either TAK-279, an approved treatment (apremilast), or a placebo for up to 61 weeks. The main goal was to see if TAK-279 reduces skin p…
Phase: PHASE3 • Sponsor: Takeda • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
Higher psoriasis drug doses show promise in small trial
Disease control CompletedThis pilot study tested higher-than-standard doses of risankizumab in 20 adults with moderate-to-severe plaque psoriasis. The goal was to see if higher doses could better reduce certain skin immune cells (resident memory T cells) and improve skin clearance. The study was complete…
Phase: PHASE2 • Sponsor: Oregon Medical Research Center • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
New shot could tame blistering skin disease and cut steroid use
Disease control CompletedThis study tested a drug called efgartigimod in 98 adults with moderate to severe bullous pemphigoid, a condition causing painful blisters and itching. The goal was to see if the drug could control the disease and allow patients to stop taking steroids. The trial was split into t…
Phase: PHASE2, PHASE3 • Sponsor: argenx • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
New drug spesolimab under Real-World watch for rare skin disease
Disease control CompletedThis study monitored 52 Japanese patients with generalized pustular psoriasis (GPP) who received spesolimab for acute symptoms. Researchers tracked side effects and disease activity in everyday clinical settings, not a controlled lab environment. The goal was to see how well the …
Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
New eczema drug shows promise in early trial
Disease control CompletedThis Phase 2 trial tested a drug called spesolimab (BI 655130) in 51 adults with moderate to severe atopic dermatitis (eczema). Participants received either the drug or a placebo intravenously. The study measured how much eczema severity changed over 16 weeks using the EASI score…
Phase: PHASE2 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
New hope for rare skin Flare-Ups: drug offered to those with no options
Disease control CompletedThis program in China gave a single infusion of spesolimab to 39 people with a severe skin condition called generalized pustular psoriasis (GPP) during a flare-up. Participants had no other treatment options available. The goal was to control the flare and monitor for side effect…
Phase: PHASE3 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
New drug for stubborn hives passes blood pressure check in phase 3 trial
Disease control CompletedThis study tested a drug called remibrutinib in 144 adults with chronic spontaneous urticaria (hives lasting over 6 months) that standard antihistamines couldn't control. Participants took a 25 mg tablet twice daily for up to 12 weeks. The main goal was to see if the drug affecte…
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
New drug shows promise for painful hand and foot pustules
Disease control CompletedThis study tested four different doses of an experimental drug (BI 655130) against a placebo in 152 adults with moderate to severe palmoplantar pustulosis (PPP), a skin condition causing painful pus-filled blisters on the palms and soles. The main goal was to see which dose best …
Phase: PHASE2 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
New rapid test for infection and inflammation put to the test
Diagnosis CompletedThis study looked at how well a new, quick finger-prick test (LumiraDx CRP) measures CRP levels compared to a standard lab test. CRP is a marker of infection, inflammation, or tissue injury. 79 adults with symptoms of these conditions took part. The goal was to see if the new tes…
Sponsor: LumiraDx UK Limited • Aim: Diagnosis
Last updated Jun 27, 2026 13:07 UTC
-
New french screening tool aims to catch eating disorders in athletes early
Diagnosis CompletedThis study is adapting and testing a French version of the Athletic Disordered Eating (ADE) scale, a 17-question screening tool designed specifically for athletes. Researchers will enroll 229 athletes aged 15 to 70 who exercise more than 6 hours per week. Participants complete th…
Phase: NA • Sponsor: University Hospital, Caen • Aim: Diagnosis
Last updated Jun 27, 2026 13:02 UTC
-
Quick vaginal infection test could beat standard diagnosis
Diagnosis CompletedThis study tested whether a rapid point-of-care test (Xpert® Xpress MVP) helps doctors diagnose vaginal infections more accurately than usual methods. 351 women with symptoms like discharge or itching were randomly assigned to either usual care or the rapid test. Researchers then…
Phase: NA • Sponsor: Sharon L Hillier • Aim: Diagnosis
Last updated Jun 27, 2026 12:05 UTC
-
MRI may replace needle biopsy for muscle disease diagnosis
Diagnosis CompletedThis study looked at whether whole body MRI can accurately diagnose inflammatory myopathies—a group of muscle diseases causing weakness and damage. Researchers compared MRI results with muscle biopsies in 139 people suspected of having these conditions. If MRI proves reliable, it…
Phase: NA • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Diagnosis
Last updated Jun 27, 2026 12:02 UTC
-
Smartphone AI could help doctors monitor skin disease remotely
Diagnosis CompletedThis study tested whether an artificial intelligence tool called Legit Health Plus can help doctors track the severity of chronic skin conditions like acne, psoriasis, and eczema from a distance. 160 participants used a smartphone app for 6 months to take photos of their skin and…
Sponsor: AI Labs Group S.L • Aim: Diagnosis
Last updated Jun 27, 2026 11:03 UTC
-
AI boosts skin diagnosis accuracy in small trial
Diagnosis CompletedThis completed study tested whether an AI device could help 16 doctors (10 general practitioners and 6 dermatologists) more accurately diagnose 13 different skin conditions, including melanoma, psoriasis, and acne. The doctors reviewed 29 medical images, first giving a diagnosis …
Sponsor: AI Labs Group S.L • Aim: Diagnosis
Last updated Jun 27, 2026 09:07 UTC
-
AI boosts skin diagnosis accuracy for GPs in small trial
Diagnosis CompletedThis study tested whether an artificial intelligence (AI) tool could help primary care doctors diagnose skin conditions more accurately. Nine doctors reviewed 30 images of various skin problems, first giving their own diagnosis and then a final diagnosis after seeing the AI's sug…
Sponsor: AI Labs Group S.L • Aim: Diagnosis
Last updated Jun 27, 2026 09:07 UTC
-
New PET tracer aims to light up hidden infections
Diagnosis CompletedThis early study tested a new radioactive tracer called 18F-FDS in 16 people with suspected bacterial or fungal infections. The tracer is designed to light up infection sites on PET/CT scans, helping doctors see exactly where an infection is. The goal was to check how the tracer …
Sponsor: Johns Hopkins University • Aim: Diagnosis
Last updated Jun 27, 2026 08:03 UTC
-
Faster, sharper fungal diagnosis: PCR kits put to the test
Diagnosis CompletedThis study looked at 120 people with suspected fungal skin infections (like athlete's foot or nail fungus). Researchers compared two different PCR test kits to see how well they could detect the fungus compared to standard lab methods. The goal was to find a faster and more relia…
Sponsor: Central Hospital, Nancy, France • Aim: Diagnosis
Last updated Jun 27, 2026 08:03 UTC
-
Which cream wins? study tests two skin protectants against diaper rash in seniors
Prevention CompletedThis study tested two different skin protection products to prevent incontinence-associated dermatitis (a type of diaper rash) in elderly nursing home residents. Researchers compared a film-forming protectant and a lipophilic (oil-based) protectant against no treatment in 220 par…
Phase: NA • Sponsor: Charite University, Berlin, Germany • Aim: Prevention
Last updated Jun 27, 2026 11:02 UTC
-
Honey heals: sweet solution may beat standard ointment for hearing aid skin woes
Prevention CompletedThis study tested whether applying medical-grade honey after bone-anchored hearing aid surgery could prevent skin breakdown better than the usual bacitracin ointment. Seventeen adults were randomly assigned to receive either honey or bacitracin for two weeks after surgery. Resear…
Phase: PHASE4 • Sponsor: Henry Ford Health System • Aim: Prevention
Last updated Jun 27, 2026 08:09 UTC
-
Could this treatment stop allergies before they start? new study in infants shows promise
Prevention CompletedThis study tested a new treatment called STMC-103H in 283 newborn babies and infants who are at high risk for developing allergies (like eczema or food allergies) because of their family history. The goal was to see if the treatment is safe and can prevent these allergic conditio…
Phase: PHASE1, PHASE2 • Sponsor: Siolta Therapeutics, Inc. • Aim: Prevention
Last updated Jun 27, 2026 07:59 UTC
-
New shot could stop GPP flares before they start
Prevention CompletedThis study tested whether a monthly injection of spesolimab can prevent flare-ups of generalized pustular psoriasis (GPP), a rare and severe skin condition. 123 people aged 12 to 75 with clear or nearly clear skin joined the trial. They received either one of three doses of speso…
Phase: PHASE2 • Sponsor: Boehringer Ingelheim • Aim: Prevention
Last updated Jun 27, 2026 07:55 UTC
-
New hope for chronic hives sufferers: experimental drug EVO756 under study
Symptom relief CompletedThis study tests an experimental drug called EVO756 in 160 adults with moderate to severe chronic spontaneous urticaria (CSU), also known as chronic hives. Participants must have had hives for at least 3 months and not gotten enough relief from standard antihistamines. The goal i…
Phase: PHASE2 • Sponsor: Evommune, Inc. • Aim: Symptom relief
Last updated Jul 03, 2026 00:00 UTC
-
New cream and app aim to ease radiation burns for cancer patients
Symptom relief CompletedThis pilot study tests whether a special cream (KeraStat) and a mobile app (MyCap) can help manage skin rashes caused by radiation therapy in head and neck cancer patients. Sixteen participants will apply the cream at least twice daily during radiation and use the app to report t…
Phase: NA • Sponsor: Wake Forest University Health Sciences • Aim: Symptom relief
Last updated Jul 01, 2026 00:00 UTC
-
Which skin glue is gentler? new study puts three to the test
Symptom relief CompletedThis study tested three different skin glues (Dermabond, Swiftset, and Liquiband) used to close small incisions after laparoscopic or robotic abdominal surgery. 180 adults each received two different glues on opposite sides of their incisions. The main goal was to see which glue …
Phase: PHASE3 • Sponsor: The University of Texas Health Science Center, Houston • Aim: Symptom relief
Last updated Jun 28, 2026 00:00 UTC
-
Can an amino acid supplement calm childhood eczema?
Symptom relief CompletedThis study tested whether a supplement containing L-histidine, along with a topical oil or lotion and unscented soap, could improve mild-to-moderate eczema in children. Forty children ages 1 to 12 were split into two groups: one received a powder supplement and the other a gummy …
Phase: NA • Sponsor: Codex Labs Corporation • Aim: Symptom relief
Last updated Jun 28, 2026 00:00 UTC
-
New gel shows promise for eczema relief
Symptom relief CompletedThis phase 2 trial tested a gel called HY209 on 210 adults with mild to moderate atopic dermatitis (eczema). The study compared different strengths of the gel to a placebo to see if it could reduce skin redness, itching, and rash. Results will show whether the gel is safe and eff…
Phase: PHASE2 • Sponsor: Shaperon • Aim: Symptom relief
Last updated Jun 27, 2026 14:02 UTC
-
New pill could tame stubborn hives
Symptom relief CompletedThis early-stage trial tested an experimental oral drug called BGB-16673 in 34 adults with chronic spontaneous urticaria (CSU), a condition causing persistent hives and itching. The study was double-blind and placebo-controlled, meaning neither patients nor doctors knew who got t…
Phase: PHASE1 • Sponsor: BeiGene • Aim: Symptom relief
Last updated Jun 27, 2026 14:00 UTC
-
App eases psoriasis burden in landmark trial
Symptom relief CompletedThis study tested a self-guided online program for people with psoriasis. 348 adults were split into two groups: one got the app plus their regular treatment, the other got regular treatment alone. The main goal was to see if the app improved quality of life over 12 months.
Phase: NA • Sponsor: Gaia AG • Aim: Symptom relief
Last updated Jun 27, 2026 14:00 UTC
-
Spray vs. ointment: which works better for incontinence rash?
Symptom relief CompletedThis study tested whether a silicone barrier spray works as well as a standard zinc oxide ointment for treating mild skin rash caused by incontinence in nursing home residents. Forty participants received one of the two treatments as part of a regular skin care routine. Researche…
Phase: NA • Sponsor: Taoyuan Armed Forces General Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 13:05 UTC
-
Simple skin care may shield kids from cancer drug side effects
Symptom relief CompletedThis study tested a preventive skin care routine in 14 children (ages 6 months to 18 years) with brain tumors who were receiving targeted therapy (BRAF, MEK, or Pan-RAF inhibitors). The goal was to see if gentle skin care and sun protection could reduce or prevent skin reactions …
Phase: PHASE2 • Sponsor: Dana-Farber Cancer Institute • Aim: Symptom relief
Last updated Jun 27, 2026 13:05 UTC
-
Could a simple skincare routine soothe psoriasis Flare-Ups?
Symptom relief CompletedThis study tests whether a daily skincare routine using Cetaphil cleansers and moisturizers can improve skin symptoms and quality of life for people with mild-to-severe plaque psoriasis. Participants apply the products to one side of their body while continuing their usual prescr…
Phase: PHASE4 • Sponsor: Galderma R&D • Aim: Symptom relief
Last updated Jun 27, 2026 13:05 UTC
-
New pill aims to give psoriasis patients their life back
Symptom relief CompletedThis study tested whether the drug deucravacitinib can improve quality of life for adults with moderate-to-severe plaque psoriasis. 180 participants received either the drug or a placebo. The main goal was to see if more people on the drug reported no or minimal impact of their s…
Phase: PHASE4 • Sponsor: Bristol-Myers Squibb • Aim: Symptom relief
Last updated Jun 27, 2026 13:00 UTC
-
New tablet shows promise for chronic hives in small study
Symptom relief CompletedThis study tested a daily tablet called NatureU Histra Disslove in 19 adults with chronic hives. Participants took one tablet before a main meal for 28 days. The study measured how well the tablet controlled hives, reduced symptoms, and improved quality of life. Results showed ch…
Phase: NA • Sponsor: OmniSolutions Laboratory Holdings Limited • Aim: Symptom relief
Last updated Jun 27, 2026 12:39 UTC
-
New shot targets cellulite: small study tests qwo on butt and thighs
Symptom relief CompletedThis completed Phase 4 study tested multiple doses of Qwo, a drug made from bacterial enzymes, for treating mild to moderate cellulite in adult women. Five participants received injections in their buttocks and thighs over three sessions. The goal was to see if the treatment impr…
Phase: PHASE4 • Sponsor: DMR Research, PLLC • Aim: Symptom relief
Last updated Jun 27, 2026 12:38 UTC
-
DIY bandage change: could self-dressing heal foot ulcers just as well?
Symptom relief CompletedThis study tested whether people with diabetic foot ulcers can safely change their own dressings compared to having a nurse do it. Sixty adults with mild to moderate ulcers were randomly assigned to either self-dressing or nurse-led dressing. The researchers tracked healing time,…
Phase: NA • Sponsor: Ain Shams University • Aim: Symptom relief
Last updated Jun 27, 2026 12:37 UTC
-
New gel shows promise for clearing acne
Symptom relief CompletedThis study tested a gel containing dapsone (7.5%) against a placebo gel in 100 adults with mild-to-moderate acne. Participants applied the gel once daily for 8 weeks, and researchers tracked changes in acne lesions, skin oil, redness, and quality of life. The goal was to see if t…
Phase: PHASE4 • Sponsor: Oya Helin Dundar • Aim: Symptom relief
Last updated Jun 27, 2026 12:37 UTC
-
New eczema cream shows promise in large trial
Symptom relief CompletedThis study tested a cream containing ruxolitinib on 241 adults with moderate atopic dermatitis (eczema) who had not gotten better with standard steroid creams. The goal was to see if the cream could improve skin clearing and reduce itching. The trial is now complete, and results …
Phase: PHASE3 • Sponsor: Incyte Corporation • Aim: Symptom relief
Last updated Jun 27, 2026 12:36 UTC
-
New foam for Kids' psoriasis shows early promise
Symptom relief CompletedThis early-phase study tested a medicated foam called ARQ-154 (roflumilast) in 22 children aged 2 to 12 with scalp and body psoriasis. The goal was to see how much of the drug enters the bloodstream and whether it is safe. Researchers monitored side effects and skin reactions ove…
Phase: PHASE1 • Sponsor: Arcutis Biotherapeutics, Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 12:36 UTC
-
Talking it out: group therapy may ease eczema symptoms
Symptom relief CompletedThis pilot study tested whether adding group psychotherapy to standard care can help adults with moderate-to-severe atopic dermatitis (eczema). Thirty-two participants were assigned to either standard care alone, standard care plus stress management and resilience training, or st…
Phase: NA • Sponsor: Semmelweis University • Aim: Symptom relief
Last updated Jun 27, 2026 12:35 UTC
-
Could a probiotic cream soothe your Child's eczema?
Symptom relief CompletedThis study tested a special moisturizing cream containing a friendly bacteria called Lactobacillus reuteri to see if it could improve eczema symptoms in children. Forty children aged 6 months to 12 years with mild-to-moderate eczema used the cream for 8 weeks. Researchers measure…
Phase: NA • Sponsor: Biogaia New Sciences AB • Aim: Symptom relief
Last updated Jun 27, 2026 12:31 UTC
-
New laser shows promise for wrinkle reduction in clinical trial
Symptom relief CompletedThis study tested a laser device (NIRA Laser M2.1) on 120 adults aged 35 and older to see if it could safely reduce full-face wrinkles. Some participants also used a topical cream after the laser. Wrinkle improvement was judged by experts looking at before-and-after photos, and p…
Phase: NA • Sponsor: NIRA Innovations Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 12:31 UTC
-
Vitamin K2 shows promise for childhood eczema
Symptom relief CompletedThis study looked at whether adding vitamin K2 to standard treatment could improve symptoms in children aged 6–12 with moderate-to-severe atopic dermatitis (eczema). For 12 weeks, 100 children received either vitamin K2 or a placebo alongside their usual care. The main goal was t…
Phase: NA • Sponsor: October 6 University • Aim: Symptom relief
Last updated Jun 27, 2026 12:31 UTC
-
New shampoo takes on dandruff in Head-to-Head trial
Symptom relief CompletedThis study tested whether a cosmetic shampoo can reduce dandruff and scalp flaking in adults with mild to moderate seborrheic dermatitis. 90 participants used the test shampoo, a standard medicated shampoo, or a regular cosmetic shampoo for 4 weeks. Researchers measured dandruff …
Phase: NA • Sponsor: Pierre Fabre Dermo Cosmetique • Aim: Symptom relief
Last updated Jun 27, 2026 12:30 UTC
-
Can a simple cream soothe psoriasis itch? small trial hopes to find out
Symptom relief CompletedThis completed study tested a moisturizing medical device called RL3020-DP0364 (Dexeryl) in 40 adults with stable mild plaque psoriasis, dry skin, and itching. Participants applied the cream to their whole body (except head) for about a month. The main goal was to see if it reduc…
Phase: NA • Sponsor: Pierre Fabre Dermo Cosmetique • Aim: Symptom relief
Last updated Jun 27, 2026 12:29 UTC
-
New ozonated hair cream cuts scalp oil by 28% in women
Symptom relief CompletedThis study tested a special cream made with ozonated oils and biotin for women with oily scalp. 66 women aged 18-40 used the cream or a placebo every night for 6 weeks. The active cream reduced scalp oil by 28%, compared to 10% for placebo, and was well-tolerated with only mild i…
Phase: NA • Sponsor: Chadi Khatib • Aim: Symptom relief
Last updated Jun 27, 2026 12:26 UTC
-
Supplements and exercise show promise for kids with muscle disease
Symptom relief CompletedThis study looked at whether taking creatine and coenzyme Q10 supplements, along with exercise, could help children with juvenile myositis (a disease that causes muscle weakness and fatigue). Fifteen children aged 7 to 18 took part. The goal was to see if these supplements could …
Phase: NA • Sponsor: The Hospital for Sick Children • Aim: Symptom relief
Last updated Jun 27, 2026 12:24 UTC
-
Psoriasis cream showdown: new formula vs. approved treatment
Symptom relief CompletedThis study compared a new tapinarof cream to an already-approved one (Vtama®) for treating plaque psoriasis, a skin condition causing red, scaly patches. 575 adults with mild to moderate psoriasis used one of the creams or a placebo for a set time. The goal was to see if the new …
Phase: PHASE1 • Sponsor: Sun Pharmaceutical Industries, Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 12:23 UTC
-
New eczema shot shows promise in Mid-Stage trial
Symptom relief CompletedThis study tested an experimental drug called lunsekimig in 150 adults with moderate-to-severe atopic dermatitis (eczema). Participants received one of three doses of the drug or a placebo as a shot under the skin for 24 weeks. The main goal was to see if the drug reduces eczema …
Phase: PHASE2 • Sponsor: Sanofi • Aim: Symptom relief
Last updated Jun 27, 2026 12:23 UTC
-
Light therapy vs. steroids: which saves your taste buds?
Symptom relief CompletedThis study looked at two treatments for oral lichen planus, a chronic mouth condition that can cause pain and change how food tastes. Researchers compared a light-based treatment (photodynamic therapy) with steroid cream in 65 adults. They measured taste ability, pain, and lesion…
Phase: NA • Sponsor: Medical University of Bialystok • Aim: Symptom relief
Last updated Jun 27, 2026 12:09 UTC
-
New light device eases mouth pain in lichen planus
Symptom relief CompletedThis study tested a home-use light device and special mouth rinse to help people with oral lichen planus, a painful mouth condition. Thirteen participants used the device daily for a year alongside standard care. The goal was to see if it could reduce pain and inflammation better…
Phase: NA • Sponsor: Koite Health Oy • Aim: Symptom relief
Last updated Jun 27, 2026 12:08 UTC
-
Silver dressing may soothe radiation burns in breast cancer patients
Symptom relief CompletedThis study tested a silver-plated wound dressing (Silverlon) in 17 breast cancer patients receiving radiation therapy. The goal was to see if the dressing could reduce the severity of acute radiation dermatitis, a common skin reaction that causes redness, peeling, and pain. Patie…
Phase: NA • Sponsor: Parul Barry • Aim: Symptom relief
Last updated Jun 27, 2026 12:08 UTC
-
New eczema cream shows promise in early trial
Symptom relief CompletedThis Phase 2 trial tested a cream called VC005 on 118 adults with mild to moderate atopic dermatitis (eczema). The study compared the cream to a placebo to see if it safely reduces eczema symptoms like itching and skin redness. Results will help decide if larger studies are warra…
Phase: PHASE2 • Sponsor: Jiangsu vcare pharmaceutical technology co., LTD • Aim: Symptom relief
Last updated Jun 27, 2026 12:07 UTC
-
New eczema cream tested in teens – early results expected
Symptom relief CompletedThis early-stage study tested a cream called VC005 in 11 adolescents aged 12 to 18 with mild to moderate eczema. The main goal was to check safety and how the body processes the drug. Researchers measured drug levels in the blood and looked for side effects.
Phase: PHASE1 • Sponsor: Jiangsu vcare pharmaceutical technology co., LTD • Aim: Symptom relief
Last updated Jun 27, 2026 12:06 UTC
-
Could a butyrate cream soothe eczema in kids without steroids?
Symptom relief CompletedThis study tested a special cream containing a butyrate releaser (a substance that helps the skin barrier) in 100 children aged 6-36 months with eczema. The cream was compared to a standard moisturizer over 12 weeks. The goal was to see if it could reduce eczema severity and impr…
Phase: NA • Sponsor: Federico II University • Aim: Symptom relief
Last updated Jun 27, 2026 12:06 UTC
-
New eczema pill shows promise in late-stage trial
Symptom relief CompletedThis study tested an experimental oral drug called LNK01001 against a placebo in 356 adults with moderate to severe atopic dermatitis (eczema) who had not responded well to creams or other treatments. The goal was to see if the drug could improve skin clearing and reduce itching …
Phase: PHASE3 • Sponsor: Lynk Pharmaceuticals Co., Ltd • Aim: Symptom relief
Last updated Jun 27, 2026 12:06 UTC
-
New lotion for Kids' psoriasis under the microscope
Symptom relief CompletedThis study looked at how a prescription lotion (IDP-118) works in children aged 4 to 16 with moderate to severe plaque psoriasis. Researchers measured how much of the drug enters the bloodstream and whether it affects the body's stress hormone system (HPA axis). The goal was to c…
Phase: PHASE4 • Sponsor: Bausch Health Americas, Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 12:06 UTC
-
Caffeine boosts weightlifting performance – but Don't expect miracles
Symptom relief CompletedThis study tested whether caffeine helps elite weightlifters perform better in competition. Fourteen athletes took either caffeine or a placebo before a simulated weightlifting meet. The results suggest caffeine can provide a small performance boost, but the effect is modest and …
Phase: NA • Sponsor: Universidad Pontificia Comillas • Aim: Symptom relief
Last updated Jun 27, 2026 12:05 UTC
-
Nano-Silver bandage promises quicker gum recovery after dark spot removal
Symptom relief CompletedThis study tested whether a nano-crystalline silver dressing helps gums heal faster and with less pain after surgical removal of dark gum pigmentation. Twelve adults with moderate to severe gum pigmentation had the surgery, and the silver dressing was compared to a standard dress…
Phase: NA • Sponsor: Damascus University • Aim: Symptom relief
Last updated Jun 27, 2026 12:05 UTC
-
Fasting for clearer skin? study tests Time-Restricted eating for psoriasis
Symptom relief CompletedThis study looked at whether intermittent fasting (eating only during certain hours) can reduce disease severity and improve quality of life for people with psoriasis and psoriatic arthritis. Sixty overweight adults were randomly assigned to either follow an intermittent fasting …
Phase: NA • Sponsor: Ohio State University • Aim: Symptom relief
Last updated Jun 27, 2026 12:05 UTC
-
New eczema drug shows promise in early trial
Symptom relief CompletedThis study tested a new drug called UCB9741 in healthy volunteers and people with moderate-to-severe atopic dermatitis (eczema). The goal was to check its safety and see if it can improve eczema symptoms. The trial involved 107 participants and compared the drug to a placebo.
Phase: PHASE1, PHASE2 • Sponsor: UCB Biopharma SRL • Aim: Symptom relief
Last updated Jun 27, 2026 12:04 UTC
-
Nasal spray may offer fast hives relief without needles
Symptom relief CompletedThis study tested a single dose of a nasal spray called ARS-1 (intranasal epinephrine) in 21 adults who get frequent hives and itching. The goal was to see if the spray works faster and better than a placebo at reducing itch and hive scores during flare-ups. Participants were mon…
Phase: PHASE2 • Sponsor: ARS Pharmaceuticals, Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 12:04 UTC
-
New ointment shows promise for eczema sufferers
Symptom relief CompletedThis study tested a new ointment called CGB-500, which contains the drug tofacitinib, for treating eczema (atopic dermatitis) in 180 people aged 12 and older. Participants applied the ointment or a placebo daily for 8 weeks. The goal was to see if it safely reduces skin redness, …
Phase: PHASE2 • Sponsor: CAGE Bio Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 12:03 UTC
-
Baking soda boost: cyclists may get an edge with common kitchen ingredient
Symptom relief CompletedThis study looked at whether taking sodium bicarbonate (baking soda) before exercise helps well-trained cyclists perform better during a long, intense ride. Nineteen athletes did two lab sessions: three hours of moderate cycling followed by a max-effort time trial. They took eith…
Phase: NA • Sponsor: University of Salzburg • Aim: Symptom relief
Last updated Jun 27, 2026 12:01 UTC
-
New eczema pill shows promise in early safety trial
Symptom relief CompletedThis early-stage trial tested a new oral drug called ENV-294 in 9 adults with moderate-to-severe atopic dermatitis (eczema). Participants took the drug once daily for 28 days and had weekly checkups. The main goal was to see if the drug is safe and tolerable, while also looking f…
Phase: PHASE1 • Sponsor: Enveda Therapeutics • Aim: Symptom relief
Last updated Jun 27, 2026 12:01 UTC
-
Which exercise focus works best for kids with rheumatic conditions?
Symptom relief CompletedThis study tested two different exercise programs in 28 children and teens with rheumatic diseases like juvenile arthritis and familial Mediterranean fever. One program used external focus (thinking about the movement's effect), the other used internal focus (thinking about the b…
Phase: NA • Sponsor: Istanbul University - Cerrahpasa • Aim: Symptom relief
Last updated Jun 27, 2026 12:01 UTC
-
New hope for nail psoriasis: tildrakizumab shows promise in trial
Symptom relief CompletedThis Phase 3 study tested the drug tildrakizumab in 99 adults with moderate to severe nail psoriasis. Participants received either the drug or a placebo for 28 weeks to see if it improved nail appearance and reduced pain. The trial is complete, and results may help determine if t…
Phase: PHASE3 • Sponsor: Sun Pharmaceutical Industries Limited • Aim: Symptom relief
Last updated Jun 27, 2026 12:01 UTC
-
Can an antioxidant boost light therapy for vitiligo?
Symptom relief CompletedThis study tested whether adding a special antioxidant pill (GLISODIN) to standard UVB light therapy helps treat vitiligo better than light therapy alone. Fifty adults with non-segmental vitiligo covering more than 5% of their body took part. The main goal was to see if the combi…
Phase: NA • Sponsor: Centre Hospitalier Universitaire de Nice • Aim: Symptom relief
Last updated Jun 27, 2026 12:00 UTC
-
Could a plant cream soothe psoriasis? new trial tests it
Symptom relief CompletedThis study tested a cream made from plant compounds (total coumarins) in 88 adults with mild-to-moderate psoriasis. Participants applied the cream or a placebo for several weeks. The goal was to see if the cream safely reduces skin redness, scaling, and thickness better than a pl…
Phase: PHASE2 • Sponsor: Psoriasis Research Institute of Guangzhou • Aim: Symptom relief
Last updated Jun 27, 2026 12:00 UTC
-
Phone therapy shows promise for psoriasis patients battling depression
Symptom relief CompletedThis study tested whether a smartphone-based cognitive behavioral therapy (CBT) program could help adults with psoriasis who also have depression symptoms. 30 participants used the app for 8 weeks with guidance from a coach. The goal was to see if people would engage with the pro…
Phase: NA • Sponsor: Brigham and Women's Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 12:00 UTC
-
Mushroom cream soothes baby skin rashes in new study
Symptom relief CompletedThis study tested a cream paste containing pleuran (a beta-glucan from oyster mushrooms) on 110 children with diaper rash, perioral dermatitis, or neonatal pustulosis. Participants applied the cream 2-3 times daily for up to 2 weeks without other treatments. Researchers measured …
Phase: NA • Sponsor: Pleuran, s.r.o. • Aim: Symptom relief
Last updated Jun 27, 2026 12:00 UTC
-
New study examines pain and adherence in patients switching to concentrated adalimumab
Symptom relief CompletedThis study involved 324 adults with conditions like Crohn's disease, arthritis, or psoriasis who switched from a standard to a higher-concentration form of adalimumab (AVT-02). Researchers measured injection site pain and how well patients stuck with their treatment over 180 days…
Sponsor: Jamp Pharma Corporation • Aim: Symptom relief
Last updated Jun 27, 2026 11:02 UTC
-
New eczema pill shows promise in early safety trial
Symptom relief CompletedThis early-stage trial tested an experimental drug called soquelitinib in 82 adults with moderate to severe atopic dermatitis (eczema). The main goal was to check safety and tolerability, while also looking for signs of symptom improvement. Participants received either the drug o…
Phase: PHASE1 • Sponsor: Corvus Pharmaceuticals, Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 11:01 UTC
-
Could a measles shot soothe eczema? small trial investigates
Symptom relief CompletedThis study tested whether a measles vaccine could help control eczema (atopic dermatitis) in adults. Researchers gave 20 adults with moderate-to-severe eczema either the measles vaccine or a placebo and tracked their symptoms for 45 days. The goal was to see if the vaccine could …
Phase: NA • Sponsor: Institut National de la Santé Et de la Recherche Médicale, France • Aim: Symptom relief
Last updated Jun 27, 2026 11:00 UTC
-
New moisturizer shows promise for dandruff relief in small study
Symptom relief CompletedThis study tested a scalp moisturizer made with celastrol and chicory root extract in 23 adults with dry, flaky scalp or dandruff. Participants applied it every night for 4 weeks. Researchers used artificial intelligence to measure changes in scalp condition. The goal was to see …
Phase: NA • Sponsor: Seoul National University Bundang Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 11:00 UTC
-
Shockwave therapy shows promise for relieving neurodermatitis itch
Symptom relief CompletedThis study tested whether extracorporeal shockwave therapy (ESWT) can reduce itching in people with neurodermatitis. Thirty-four adults aged 55 to 75 received four weekly sessions of shockwaves applied to the skin. The main goal was to measure changes in itch severity using a sta…
Phase: NA • Sponsor: Cairo University • Aim: Symptom relief
Last updated Jun 27, 2026 11:00 UTC
-
Insulin ointment shows promise for speeding up wound healing in rare blistering disease
Symptom relief CompletedThis study tested whether applying insulin directly to skin sores helps them heal faster in people with pemphigus vulgaris, a rare autoimmune blistering disease. Twenty patients each had three similar sores treated with either long-acting insulin, short-acting insulin, or a saltw…
Phase: PHASE2 • Sponsor: Alexandria University • Aim: Symptom relief
Last updated Jun 27, 2026 11:00 UTC
-
Could a natural compound help clear acne and scars?
Symptom relief CompletedThis study tested whether a cream made from icariin, a plant compound, can improve acne and reduce acne scars. Twenty-five adults applied the cream or a control solution to their face twice daily for two months. The goal was to see if it lowers the number of pimples and scars and…
Phase: NA • Sponsor: Seoul National University Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 09:11 UTC
-
Insulin dressing shows promise for diabetic foot ulcers
Symptom relief CompletedThis study tested whether applying insulin directly to diabetic foot ulcers helps them heal better than standard saline dressings. Thirty adults with diabetes and foot ulcers participated. Researchers measured healing rates and whether surgery was needed.
Phase: NA • Sponsor: Cairo University • Aim: Symptom relief
Last updated Jun 27, 2026 09:07 UTC
-
CBD drug shows promise for OCD and tics in tiny study
Symptom relief CompletedThis small study tested whether Epidiolex (a prescription CBD oil) can safely reduce symptoms of obsessive-compulsive disorder, hair-pulling, Tourette syndrome, and hoarding. Four adults took the drug for two weeks. The goal was to see if symptoms improved and if the drug was wel…
Phase: PHASE2 • Sponsor: University of Chicago • Aim: Symptom relief
Last updated Jun 27, 2026 09:04 UTC
-
New antibody takes aim at psoriasis in first human trial
Symptom relief CompletedThis early-stage study tested a new drug called CAN10, an antibody that blocks a protein involved in inflammation. Researchers gave single doses to 80 healthy adults and repeated doses to people with mild to moderate plaque psoriasis to see if it is safe and how the body processe…
Phase: PHASE1 • Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 09:02 UTC
-
New hope for teens with stubborn hives: xolair shows promise
Symptom relief CompletedThis study looked at whether Xolair (omalizumab) is safe and works for Chinese teenagers with chronic spontaneous urticaria (long-term hives and itching) that doesn't get better with standard antihistamines. 55 teens took part, receiving Xolair for 12 weeks, followed by 4 weeks o…
Sponsor: Novartis Pharmaceuticals • Aim: Symptom relief
Last updated Jun 27, 2026 09:01 UTC
-
Ear spray showdown: can ectoin soothe outer ear itch?
Symptom relief CompletedThis study looked at two ear sprays—Ectoin Ear Spray and Normison Ear Spray—to see how well they work and if they are safe for people with chronic itching and skin irritation of the outer ear canal. 60 adults took part in this real-world observation. The main goal was to check if…
Sponsor: Bitop AG • Aim: Symptom relief
Last updated Jun 27, 2026 09:00 UTC
-
New psoriasis pill shows promise in Mid-Stage trial
Symptom relief CompletedThis study tested an experimental drug called TQH3906 in 209 adults with moderate to severe plaque psoriasis. The goal was to see if it could safely clear skin patches and improve symptoms over 12 weeks. Researchers measured how much skin improved using standard psoriasis scores.
Phase: PHASE2 • Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. • Aim: Symptom relief
Last updated Jun 27, 2026 09:00 UTC
-
New pill for eczema shows promise in early safety trial
Symptom relief CompletedThis early-stage study tested an oral medication called KT-621 in 22 adults with moderate to severe atopic dermatitis (eczema). The main goal was to check safety and how the body processes the drug. Researchers monitored side effects and drug levels in the blood, but did not meas…
Phase: PHASE1 • Sponsor: Kymera Therapeutics, Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 08:15 UTC
-
Which pill stops the itch? new study pits bilastine against levocetirizine for hives
Symptom relief CompletedThis study tested two different antihistamine treatments in 60 adults with chronic hives (itchy welts that keep coming back). One group took a higher dose of bilastine, the other took a mix of bilastine and levocetirizine. The goal was to see which approach better reduces itching…
Phase: NA • Sponsor: Derma Techno Pakistan • Aim: Symptom relief
Last updated Jun 27, 2026 08:14 UTC
-
New hope for kids with rare swelling disorder: sebetralstat shows promise
Symptom relief CompletedThis study tested a drug called sebetralstat in 36 children aged 2 to 11 with hereditary angioedema (HAE) types I or II, a condition that causes sudden, painful swelling. The goal was to see if the drug is safe and how well it works to relieve attacks. The trial was open-label, m…
Phase: PHASE3 • Sponsor: KalVista Pharmaceuticals, Ltd. • Aim: Symptom relief
Last updated Jun 27, 2026 08:13 UTC
-
New psoriasis drug shows promise in Mid-Stage trial
Symptom relief CompletedThis study tested an experimental drug called SCD-044 in 263 adults with moderate to severe plaque psoriasis. Participants received either the drug or a placebo to see if it could improve skin symptoms like redness and scaling. The main goal was to measure how many people achieve…
Phase: PHASE2 • Sponsor: Sun Pharmaceutical Industries Limited • Aim: Symptom relief
Last updated Jun 27, 2026 08:13 UTC
-
Tattoo machine vs. needle: new hope for women with genital skin disease?
Symptom relief CompletedThis study tested two ways to inject a cortisone medicine (triamcinolone acetonide) to treat genital lichen sclerosus, a skin condition causing itching, pain, and discomfort in women. Twenty women who did not improve with standard creams received injections either by a traditiona…
Phase: NA • Sponsor: Clinica Dermatologica Arbache ltda • Aim: Symptom relief
Last updated Jun 27, 2026 08:13 UTC
-
Can a diabetes drug beat acne? new study says maybe
Symptom relief CompletedThis study tested whether the diabetes drug metformin can treat moderate to severe facial acne as well as the antibiotic doxycycline. Sixty-eight people aged 12 to 40 took either metformin twice daily or doxycycline once daily for 12 weeks. Researchers counted pimples and used a …
Phase: PHASE4 • Sponsor: Ghurki Trust and Teaching Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 08:13 UTC
-
New eczema ointment shows promise in early trial
Symptom relief CompletedThis study tested an experimental ointment called LNK01004 in 75 adults with moderate-to-severe atopic dermatitis (eczema). Participants applied the ointment twice daily for 8 weeks. The goal was to see if it reduces skin redness, swelling, and itching better than a placebo ointm…
Phase: PHASE2 • Sponsor: Lynk Pharmaceuticals Co., Ltd • Aim: Symptom relief
Last updated Jun 27, 2026 08:11 UTC
-
Acne breakthrough? ear acupressure boosts standard Gel's power
Symptom relief CompletedThis study tested whether adding ear acupressure to a standard acne gel (adapalene) helps clear pimples better than the gel alone. Researchers enrolled 64 people with mild to moderate acne and compared the combination to the gel-only group. The goal was to see if the combo reduce…
Phase: NA • Sponsor: University of Medicine and Pharmacy at Ho Chi Minh City • Aim: Symptom relief
Last updated Jun 27, 2026 08:11 UTC
-
New drug shows promise for teens with stubborn hives
Symptom relief CompletedThis study tested a drug called ligelizumab in 49 teenagers aged 12 to 17 who had chronic hives (itchy welts) that didn't get better with standard allergy pills. The goal was to see if adding ligelizumab to their current treatment could reduce the number and severity of hives. Pa…
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Symptom relief
Last updated Jun 27, 2026 08:10 UTC
-
Could a daily probiotic soothe baby eczema?
Symptom relief CompletedThis study tested whether a daily probiotic called Bifidobacterium longum CCFM1029 can reduce eczema symptoms in infants aged 3 months to 3 years. One hundred children with atopic dermatitis were split into two groups: one received the probiotic and the other a placebo for 3 mont…
Phase: NA • Sponsor: Glac Biotech Co., Ltd • Aim: Symptom relief
Last updated Jun 27, 2026 08:10 UTC
-
New bandage may soothe radiation burns in breast cancer patients
Symptom relief CompletedThis study tested a special dressing coated with a substance that binds bacteria (DACC-coated hydrogel) to treat skin burns caused by radiation therapy in 18 women with breast cancer. The goal was to see if it could reduce pain and help heal the skin. The study is already complet…
Sponsor: I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio • Aim: Symptom relief
Last updated Jun 27, 2026 08:10 UTC
-
New pill for Kids' eczema itch shows promise in large trial
Symptom relief CompletedThis study tested whether a new oral medicine called TAU-284 (bepotastine besilate) can reduce itching in children aged 7 to 15 with atopic dermatitis (eczema). Over 300 children took either TAU-284 or an older medicine (ketotifen) twice daily for several weeks. The main goal was…
Phase: PHASE3 • Sponsor: Tanabe Pharma Corporation • Aim: Symptom relief
Last updated Jun 27, 2026 08:09 UTC
-
New pill shows promise for nail psoriasis in first human test
Symptom relief CompletedThis early-phase study tested deucravacitinib, an oral drug, for treating nail psoriasis. The goal was to see if it improves nail appearance and symptoms. Only one person took part, and researchers measured changes in nail psoriasis severity over 48 weeks. Because it's so small, …
Phase: EARLY_PHASE1 • Sponsor: University of Alabama at Birmingham • Aim: Symptom relief
Last updated Jun 27, 2026 08:09 UTC
-
Could selenium soothe painful mouth sores?
Symptom relief CompletedThis study tested whether a selenium gel can help treat oral lichen planus, a chronic condition that causes painful sores in the mouth. Fifty adults with the condition used either selenium gel, a standard steroid cream, or an immunosuppressant cream. The goal was to see if seleni…
Phase: PHASE4 • Sponsor: Al-Azhar University • Aim: Symptom relief
Last updated Jun 27, 2026 08:07 UTC
-
New acne cream shows promise in small safety trial
Symptom relief CompletedPfizer completed a Phase 1 study testing a new topical drug called PF-07905428 for acne. The study included 52 healthy volunteers and people with moderate to severe acne, who applied the drug daily for 14 or 28 days. The main goal was to check safety and side effects, not to see …
Phase: PHASE1 • Sponsor: Pfizer • Aim: Symptom relief
Last updated Jun 27, 2026 08:07 UTC
-
New moisturizer shows promise for Acne-Prone skin in small study
Symptom relief CompletedThis study tested a facial moisturizer in 47 people with mild to moderate acne over 4 weeks. Researchers checked skin dryness, redness, and overall appearance, and participants reported how their skin felt. The goal was to see if the moisturizer is gentle and helpful for acne-pro…
Phase: NA • Sponsor: Kenvue Brands LLC • Aim: Symptom relief
Last updated Jun 27, 2026 08:07 UTC
-
CBD cream shows promise for eczema itch relief in small study
Symptom relief CompletedThis 56-day study tested a cream containing CBD and cherimoya fruit extract on 42 children and adults with mild-to-moderate atopic dermatitis (eczema). Participants applied the cream twice daily. Researchers measured skin redness, dryness, itching, and sleep quality. The goal was…
Phase: NA • Sponsor: i+Med S.Coop. • Aim: Symptom relief
Last updated Jun 27, 2026 08:07 UTC
-
Personalized rehab shows promise for rare muscle diseases
Symptom relief CompletedThis study tested whether a personalized exercise program can improve daily function and quality of life for people with dermatomyositis or polymyositis, two rare diseases that cause muscle weakness and inflammation. 80 adults with stable muscle impairment took part. The program …
Phase: PHASE2 • Sponsor: University Hospital, Lille • Aim: Symptom relief
Last updated Jun 27, 2026 08:06 UTC
-
New eczema cream shows promise for kids ages 2-5
Symptom relief CompletedThis study tested a cream called ARQ-151 on 652 children aged 2 to 5 with eczema (atopic dermatitis). The cream was applied once daily for 4 weeks. The goal was to see if it could clear or nearly clear the skin rash better than a cream with no active ingredient. The study is comp…
Phase: PHASE3 • Sponsor: Arcutis Biotherapeutics, Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 08:06 UTC
-
New drug offers hope for rare swelling disorder patients
Symptom relief CompletedThis study tested a drug called icatibant (Icanticure) in 5 adults with a rare condition that causes sudden, painful swelling attacks. The goal was to see how quickly the drug relieved symptoms and if it was safe. Participants received the injection for free during an acute attac…
Phase: PHASE4 • Sponsor: Nang Kuang Pharmaceutical Co., Ltd. • Aim: Symptom relief
Last updated Jun 27, 2026 08:05 UTC
-
New eczema ointment shows promise in early trial
Symptom relief CompletedThis study tested a new ointment called YR001 in 35 adults with mild to moderate atopic dermatitis (eczema). The main goal was to check if the ointment is safe and how the body processes it. Researchers also looked at whether it improves skin condition. The trial was completed an…
Phase: PHASE2 • Sponsor: Hangzhou Yirui Pharmaceutical Technology Co., Ltd • Aim: Symptom relief
Last updated Jun 27, 2026 08:05 UTC
-
Itch-Busting cream shows promise for painful skin bumps
Symptom relief CompletedThis Phase 3 trial tested a cream called ruxolitinib (also known as Opzelura) in 190 adults with prurigo nodularis, a skin condition causing intense itching and hard bumps. Participants applied the cream twice daily for 12 weeks. The main goal was to see if it could reduce itch b…
Phase: PHASE3 • Sponsor: Incyte Corporation • Aim: Symptom relief
Last updated Jun 27, 2026 08:05 UTC
-
New drug 9MW1911 tested for safety in first human trial
Symptom relief CompletedThis Phase 1 trial tested the safety and tolerability of a new drug called 9MW1911 in 48 healthy adults. The drug is being developed for asthma, COPD, and atopic dermatitis. Participants received either the drug or a placebo by IV infusion, and researchers monitored side effects …
Phase: PHASE1 • Sponsor: Mabwell (Shanghai) Bioscience Co., Ltd. • Aim: Symptom relief
Last updated Jun 27, 2026 08:04 UTC
-
New pill could stop painful swelling attacks in rare disease
Symptom relief CompletedThis study tested an oral medication called deucrictibant for quickly relieving swelling and pain attacks in people with hereditary angioedema (HAE) types I and II. 74 adults received either one of three doses of the drug or a placebo during an attack. The main goal was to see if…
Phase: PHASE2 • Sponsor: Pharvaris Netherlands B.V. • Aim: Symptom relief
Last updated Jun 27, 2026 08:04 UTC
-
Probiotics show promise for acne relief
Symptom relief CompletedThis study looked at whether taking probiotics can reduce a protein in the blood linked to acne inflammation. Researchers measured this protein in 50 adults with mild to moderate acne before and after probiotic treatment. The goal was to see if probiotics could help ease acne sym…
Sponsor: Benha University • Aim: Symptom relief
Last updated Jun 27, 2026 08:03 UTC
-
New eczema cream shows promise for infants in safety trial
Symptom relief CompletedThis study tested a cream called roflumilast (0.05%) applied once daily for 4 weeks in 101 infants aged 3 months to 2 years with mild-to-moderate eczema. The main goal was to see if the cream is safe and well-tolerated. Researchers tracked side effects, serious side effects, and …
Phase: PHASE2 • Sponsor: Arcutis Biotherapeutics, Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 08:03 UTC
-
New eczema drug shows promise in early trial
Symptom relief CompletedThis early-stage study tested a new medicine called BMS-986326 in 64 adults with moderate-to-severe atopic dermatitis (eczema) who did not get enough relief from creams or needed stronger treatments. The main goal was to check the drug's safety and how the body processes it. Rese…
Phase: PHASE1 • Sponsor: Bristol-Myers Squibb • Aim: Symptom relief
Last updated Jun 27, 2026 08:02 UTC
-
Birch bark gel shows promise for healing radiation burns in breast cancer
Symptom relief CompletedThis study tested whether a gel made from birch bark extract (Oleogel-S10) can help heal skin burns caused by radiation therapy in breast cancer patients. 18 women with moderate to severe radiation dermatitis used the gel along with a standard steroid cream. The goal was to see i…
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Symptom relief
Last updated Jun 27, 2026 08:01 UTC
-
New eczema drug shows promise in early trial
Symptom relief CompletedThis study tested an experimental drug, EVO301, in 71 adults with moderate-to-severe atopic dermatitis (eczema). The goal was to see if it safely reduces skin redness, thickness, and itch. Participants received either EVO301 or a placebo, and doctors measured changes in skin seve…
Phase: PHASE2 • Sponsor: Evommune, Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 08:01 UTC
-
New gel shows promise for dark skin patches
Symptom relief CompletedThis small study tested a gel containing sirolimus (0.2%) on 5 adults with acanthosis nigricans, a condition causing dark, thick skin patches. The goal was to see if the gel safely lightens the skin and improves texture over 12 weeks. Researchers measured changes in skin color an…
Phase: PHASE2 • Sponsor: Narrows Institute for Biomedical Research • Aim: Symptom relief
Last updated Jun 27, 2026 08:00 UTC
-
Eye movement therapy shows promise for itchy skin conditions
Symptom relief CompletedThis study tested a behavioral therapy called EMD-U in 96 adults with atopic dermatitis or prurigo nodularis who had a strong urge to scratch. The therapy involves focusing on the itchy spot while moving the eyes, repeated until the urge fades. Researchers compared EMD-U plus usu…
Phase: NA • Sponsor: Tamar Nijsten • Aim: Symptom relief
Last updated Jun 27, 2026 07:59 UTC
-
Diet showdown: can keto or mediterranean ease psoriasis and joint pain?
Symptom relief CompletedThis study tested whether an 8-week ketogenic or Mediterranean diet could reduce inflammation in 26 adults with obesity, psoriasis, and psoriatic arthritis. Participants followed one of the two diets, and researchers measured skin severity (PASI score) and joint activity (DAPSA s…
Phase: NA • Sponsor: Attikon Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 07:58 UTC
-
Firazyr tested in kids with rare swelling disorder
Symptom relief CompletedThis study in Japan looked at 32 children (ages 2 to under 18) with hereditary angioedema who received Firazyr injections for acute attacks. Researchers tracked side effects and how quickly symptoms resolved over 3 months. The goal was to gather real-world safety and effectivenes…
Sponsor: Takeda • Aim: Symptom relief
Last updated Jun 27, 2026 07:57 UTC
-
New cream offers hope for unbearable itch
Symptom relief CompletedThis Phase 3 trial tested a cream containing ruxolitinib in 204 adults with prurigo nodularis, a skin condition causing intense itching and hard bumps. Participants applied the cream twice daily for 12 weeks. The main goal was to see if it reduced itch by at least 4 points on a 0…
Phase: PHASE3 • Sponsor: Incyte Corporation • Aim: Symptom relief
Last updated Jun 27, 2026 07:57 UTC
-
New acne gel shows promise in Head-to-Head trial
Symptom relief CompletedThis Phase 2 trial tested a new acne gel called IDP-126 against a standard gel (Epiduo Forte) and a placebo gel in 686 people aged 12 and older with moderate to severe acne. Participants applied the gel once daily for 12 weeks. Researchers measured changes in acne lesion counts a…
Phase: PHASE2 • Sponsor: Bausch Health Americas, Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 07:56 UTC
-
New shot shows promise for tough eczema cases
Symptom relief CompletedThis study tested an experimental drug called BSI-045B in 22 adults with moderate to severe atopic dermatitis (eczema). Participants received injections weekly for 4 weeks, then every 2 weeks up to 24 weeks. The main goals were to see if the drug safely reduces eczema severity by…
Phase: PHASE2 • Sponsor: Biosion, Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 07:54 UTC
-
Scientists track severe allergies to uncover hidden patterns
Knowledge-focused CompletedThis completed study followed 945 people, mostly children and young adults with severe eczema or related allergic conditions, along with their relatives. Researchers observed how these diseases progress over up to a year, using tests like allergy skin pricks, blood draws, and lun…
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Knowledge-focused
Last updated Jul 04, 2026 00:00 UTC
-
Psoriasis study probes hidden heart risks
Knowledge-focused CompletedThis completed study looked at 386 adults with psoriasis to understand how skin inflammation might be linked to heart and blood vessel diseases. Participants had up to seven visits over four years, including blood tests, heart scans, and optional skin biopsies. The goal was to se…
Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Knowledge-focused
Last updated Jul 04, 2026 00:00 UTC
-
Acne Drug's hidden toll on the eye revealed
Knowledge-focused CompletedThis study looks at how isotretinoin, a vitamin A-based acne medication, affects eye structures and tear production in people with severe cystic acne. Participants receive standard treatment and undergo eye exams, including dry eye tests and advanced imaging, before and during th…
Phase: NA • Sponsor: Demet Mutlu • Aim: Knowledge-focused
Last updated Jul 02, 2026 00:00 UTC
-
Study explores how family and friends impact caregiver health
Knowledge-focused CompletedThis completed study looked at how the social networks of caregivers affect their stress and health when caring for someone with an inherited disease. Researchers surveyed over 680 participants, including family members and formal caregivers, to understand caregiving burden and s…
Sponsor: National Human Genome Research Institute (NHGRI) • Aim: Knowledge-focused
Last updated Jul 02, 2026 00:00 UTC
-
Do future doctors know the skin risks of tattoos and piercings?
Knowledge-focused CompletedThis study surveys medical students to understand their attitudes toward tattoos and piercings and measure their awareness of related skin risks, such as infections, allergic reactions, and scarring. Researchers aim to see if students have adequate knowledge and how their views d…
Sponsor: Biruni University • Aim: Knowledge-focused
Last updated Jul 01, 2026 00:00 UTC
-
Psoriasis Drug's skin gene secrets revealed in small trial
Knowledge-focused CompletedThis study looked at how the drug adalimumab affects gene activity in the skin of people with chronic plaque psoriasis. Researchers compared skin samples from normal, non-lesional, and lesional areas before and after treatment. The goal was to understand the immune changes that h…
Phase: PHASE2 • Sponsor: Poitiers University Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:03 UTC
-
Military myositis mystery: could exposures be the trigger?
Knowledge-focused CompletedThis study investigated whether environmental exposures during military service increase the risk of developing myositis, a rare autoimmune disease that attacks muscles. Researchers compared 37 military personnel with and without myositis using questionnaires and blood samples. N…
Sponsor: National Institute of Environmental Health Sciences (NIEHS) • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
Jump start: simple Warm-Up trick may improve speed and stability
Knowledge-focused CompletedThis study looked at whether doing drop jumps during warm-up helps young basketball players jump higher, sprint faster, and land more stably. Twenty-two athletes were split into two groups: one added drop jumps to their warm-up for 8 weeks, the other did not. Researchers measured…
Phase: NA • Sponsor: University of Palermo • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
Scientists hunt for genetic and environmental triggers of rare muscle diseases
Knowledge-focused CompletedThis study looked at 719 people, including patients with autoimmune connective tissue diseases like myositis, their blood relatives, and healthy volunteers. Researchers collected blood samples and medical histories to find genetic and environmental factors that may trigger these …
Sponsor: National Institute of Environmental Health Sciences (NIEHS) • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Pedal power: strength training boosts cyclist performance, but gains fade
Knowledge-focused CompletedThis study looked at whether adding strength training to regular cycling workouts helps competitive cyclists improve performance and muscle function. Twenty-four male cyclists either did strength training plus endurance training or just endurance training for 10 weeks. Researcher…
Phase: NA • Sponsor: Lithuanian Sports University • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
AI writes acne guide, students score same as human version
Knowledge-focused CompletedThis study tested whether AI-generated educational material on acne could teach medical students as well as standard human-written material. 190 first- and second-year medical students were split into three groups: one read AI-generated content, one read content from the Turkish …
Phase: NA • Sponsor: Hasan Durmuş • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Study reveals bone risks from common skin treatment
Knowledge-focused CompletedThis study looked at 47 people with bullous pemphigoid, a blistering skin condition, who were treated with high-dose topical corticosteroids (clobetasol propionate) for 6 months. Researchers measured bone mineral density at the start, at 3 months, and at 6 months to see if the tr…
Phase: PHASE4 • Sponsor: Centre Hospitalier Universitaire, Amiens • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:07 UTC
-
New hives drug candidate takes first step in human safety trial
Knowledge-focused CompletedThis early-stage study tests a new oral drug called HRS-3095 in 66 healthy adults aged 18-55. The main goal is to check safety and how the body processes the drug, not to treat any disease. Results will help design future studies for chronic spontaneous urticaria (long-term hives…
Phase: PHASE1 • Sponsor: Chengdu Suncadia Medicine Co., Ltd. • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:05 UTC
-
New study tests if food changes how a skin drug works
Knowledge-focused CompletedThis study looks at how taking VC005 tablets with or without food changes the drug's levels in the blood. It involves 30 healthy adults aged 18 to 45. The goal is to gather information to help design future studies for atopic dermatitis (eczema). Participants will take the drug t…
Phase: PHASE1 • Sponsor: Jiangsu vcare pharmaceutical technology co., LTD • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:05 UTC
-
French study maps scalp ringworm fungi and drug resistance
Knowledge-focused CompletedThis completed study looked at scalp ringworm, a common fungal infection in children, across 11 French centers in 2023. Researchers collected 701 fungal samples to identify the species and test their sensitivity to common antifungal drugs. The goal was to understand which fungi c…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:04 UTC
-
Scientists decode Eczema's genetic fingerprints in major skin study
Knowledge-focused CompletedThis study looked at the genes in the skin of 433 people with eczema (atopic dermatitis) to find patterns that separate mild from severe cases. Researchers collected skin samples and tracked how these patterns changed with standard treatments like steroid creams and dupilumab. Th…
Phase: PHASE4 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:03 UTC
-
Study reveals vaccine response in Immune-Compromised patients
Knowledge-focused CompletedThis study looked at how people with autoimmune diseases like multiple sclerosis or blistering skin conditions respond to COVID-19 vaccines while on B-cell depleting therapies. Researchers measured antibody levels and T-cell activity over time to understand vaccine effectiveness …
Sponsor: Yale University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:38 UTC
-
Psoriasis breakthrough? single shot may keep skin clear for over a year
Knowledge-focused CompletedThis study looked at 24 adults with moderate-to-severe plaque psoriasis to understand how a single injection of risankizumab (Skyrizi) changes immune cells in the skin. The goal was to learn why some patients stay clear of psoriasis for up to 66 weeks without further treatment. R…
Phase: PHASE4 • Sponsor: Jaehwan Kim • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:37 UTC
-
New study aims to predict painful skin rash in hospital patients
Knowledge-focused CompletedThis study looked at 271 hospital patients with incontinence to find out which factors most strongly predict a common skin problem called incontinence-associated dermatitis (IAD). Researchers tracked things like age, stool consistency, and mobility, checking patients' skin daily.…
Sponsor: Örebro University, Sweden • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:37 UTC
-
Time-Restricted eating shows promise for psoriasis inflammation
Knowledge-focused CompletedThis pilot study tested whether time-restricted feeding (eating all daily calories between 8am and 2pm, then fasting for 18 hours) could reduce inflammation in men with mild to moderate psoriasis. 27 participants (including healthy volunteers) stayed at the clinic for 4.5 days, w…
Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:33 UTC
-
Oxygen therapy may give athletes an edge
Knowledge-focused CompletedThis study tested whether 40 sessions of hyperbaric oxygen therapy (breathing pure oxygen in a pressurized chamber) could improve aerobic and anaerobic fitness in healthy athletes. 59 participants, aged 18-25 or 40-50, underwent either real or sham treatment over two months. Rese…
Phase: NA • Sponsor: Assaf-Harofeh Medical Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:33 UTC
-
New moisturizer study seeks to understand eczema patients on strong medications
Knowledge-focused CompletedThis study looked at how adults with moderate-to-severe atopic dermatitis (eczema) that is controlled by systemic treatments (like pills or injections) use and feel about a cosmetic moisturizer called RV4427C WM0071. The goal was to understand their needs, expectations, and how s…
Sponsor: Pierre Fabre Dermo Cosmetique • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:32 UTC
-
Moisturizer habits of eczema patients under systemic therapy revealed
Knowledge-focused CompletedThis study looked at 80 adults with moderate-to-severe atopic dermatitis (eczema) whose condition is controlled by systemic treatments. Researchers wanted to understand how these patients use moisturizers and what they expect from them. Participants filled out questionnaires abou…
Sponsor: Pierre Fabre Dermo Cosmetique • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
Lichen planus may mess with your sense of smell and taste, study finds
Knowledge-focused CompletedThis completed study looked at whether lichen planus, a chronic inflammatory condition, affects smell and taste. 88 adults (patients and healthy controls) took smell and taste tests and had oral and nasal exams. The goal was to see if mucosal involvement is linked to sensory chan…
Sponsor: Istanbul Training and Research Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
Eczema drug Tralokinumab's eye risks under the microscope
Knowledge-focused CompletedThis study looked at 100 adults with atopic dermatitis (eczema) who were prescribed tralokinumab. Researchers tracked how many developed eye problems like conjunctivitis within 4 months of starting the drug. The goal was to better understand these side effects in real-world use, …
Sponsor: Nantes University Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:28 UTC
-
Super shoes under scrutiny: do they lead to more injuries?
Knowledge-focused CompletedThis study looked at 134 competitive runners to see if advanced footwear technology (AFT) — the springy, carbon-fiber shoes many elite athletes wear — is linked to more muscle and tendon injuries. Researchers surveyed athletes about their training habits and injury history over t…
Sponsor: University of Oviedo • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:28 UTC
-
Hockey hand injuries under the microscope: new study aims to protect players
Knowledge-focused CompletedThis completed study looked at hand and wrist injuries in professional hockey players in the Swedish Hockey League over three seasons. Researchers analyzed injury data from about 2,300 games to understand what types of injuries happen, when they occur, and which players are most …
Sponsor: Dalarna County Council, Sweden • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:25 UTC
-
Can a Nurse-Led program help psoriasis patients take control?
Knowledge-focused CompletedThis pilot study tested a nurse-led educational program for people with psoriasis. Twenty-four participants received extra education sessions over six weeks, alongside standard care. The goal was to see if the program was feasible and could improve disease knowledge, self-managem…
Phase: NA • Sponsor: School of Health Sciences Geneva • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:24 UTC
-
HAE patients and caregivers speak out: the hidden costs of On-Demand treatment
Knowledge-focused CompletedThis completed French survey of 300 hereditary angioedema (HAE) patients and their caregivers aimed to understand the challenges of using on-demand treatments for HAE attacks. Researchers collected data on attack frequency, severity, treatment delays, hospitalizations, and the fi…
Sponsor: University Hospital, Grenoble • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:24 UTC
-
Heat-Sensing cameras may spot volleyball injuries before they happen
Knowledge-focused CompletedThis study tested whether thermal imaging (a camera that measures body heat) can reliably assess injury risk in volleyball players. Researchers compared thermal images with standard performance tests like vertical jumps and balance assessments in 33 amateur and professional playe…
Sponsor: Biruni University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
Eczema drug interaction study completed: what it means for patients
Knowledge-focused CompletedThis study looked at how a new drug called amlitelimab affects the way the body processes other medications in adults with moderate-to-severe atopic dermatitis (eczema). 23 participants received amlitelimab and a cocktail of common drugs to measure changes in drug levels. The goa…
Phase: PHASE1 • Sponsor: Sanofi • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
Real-World data reveals omalizumab prescribing patterns for chronic hives in china
Knowledge-focused CompletedThis study examined how the drug omalizumab is prescribed in real-world practice for adults with chronic urticaria (long-term hives) in China. Researchers analyzed electronic health records from over 3,400 patients to see what doses were commonly used. The goal was to understand …
Sponsor: Novartis Pharmaceuticals • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:07 UTC
-
Eczema Drug's impact on vaccines under microscope
Knowledge-focused CompletedThis study looked at how well vaccines work in adults with moderate-to-severe eczema who are taking amlitelimab, an experimental drug. About 224 participants received either amlitelimab or a placebo along with tetanus and pneumonia vaccines. The goal was to see if the drug change…
Phase: PHASE2 • Sponsor: Sanofi • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:06 UTC
-
New antibody tested in healthy volunteers – no cure yet
Knowledge-focused CompletedThis early-stage study tested a single dose of the experimental antibody SM17 in 30 healthy Chinese adults to see if it is safe and how the body processes it. The study did not aim to treat any disease. Results will help plan future trials for conditions like eczema, asthma, and …
Phase: PHASE1 • Sponsor: SinoMab BioScience Ltd • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:04 UTC
-
Scientists investigate protein link in skin diseases
Knowledge-focused CompletedThis study looked at skin samples from 170 people with psoriasis, atopic dermatitis (eczema), or healthy skin to understand how a protein called Lyn is involved in inflammation. Researchers measured Lyn activity and related enzymes in both affected and unaffected skin. The goal w…
Phase: NA • Sponsor: Centre Hospitalier Universitaire de Nice • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:02 UTC
-
High-Tech suits tested on cyclists – do they really work?
Knowledge-focused CompletedThis study tested whether full-body suits made with far-infrared (FIR) emitting fibers affect body temperature, heart rate, oxygen use, and power output in young competitive cyclists. Nine cyclists rode a stationary bike for 40 minutes at a steady pace, then did a 5-second sprint…
Phase: NA • Sponsor: University of Palermo • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:01 UTC
-
Scientists probe genetic roots of Cold-Triggered hives
Knowledge-focused CompletedThis study looks at why some people develop hives from physical triggers like cold, pressure, or sunlight. Researchers will test participants' skin reactions and collect blood and genetic samples to understand the role of immune cells and genes. The goal is to uncover the underly…
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:01 UTC
-
Scabies cure rates under the microscope: national study reveals treatment success
Knowledge-focused CompletedThis completed Italian study looked at over 1,300 people with scabies to see how often the first treatment cured them. Researchers also tracked how many scabies cases occurred over three years and analyzed patterns by age and ethnicity. The study did not test a new drug but colle…
Sponsor: Societa Italiana di Dermatologia Medica, Chirurgica, Estetica e di Malattie Sessualmente Trasmesse • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:01 UTC
-
Psoriasis patients' satisfaction with biologics: it's not just about skin clearance
Knowledge-focused CompletedThis completed study looked at 52 adults with plaque psoriasis who had been on biologic drugs for at least one year. Researchers used questionnaires to measure treatment satisfaction, quality of life, depression, and personality type. The goal was to find out which clinical and p…
Sponsor: Catholic University of the Sacred Heart • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:00 UTC
-
Could a common virus fuel painful mouth disease?
Knowledge-focused CompletedThis study explored whether the Epstein-Barr virus (EBV) contributes to inflammation in oral lichen planus, a chronic mouth condition that can be painful. Researchers measured levels of EBV genetic material in 13 adults with the atrophic or erosive form of the disease. The goal w…
Phase: NA • Sponsor: Centre Hospitalier Universitaire de Nice • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:00 UTC
-
New tool aims to better measure psoriasis burden over a lifetime
Knowledge-focused CompletedThis study tested a new questionnaire called DermCLCI-p to see if it accurately measures the long-term life impacts of moderate-to-severe psoriasis. 154 adults starting the medication risankizumab filled out the 30-question survey over 28 weeks. The goal was to validate the tool …
Sponsor: AbbVie • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:00 UTC
-
Vibrating platforms change reflex timing, small study finds
Knowledge-focused CompletedThis study looked at how standing on a vibrating platform affects spinal reflexes in 15 healthy adults. Participants stood in different positions with or without vibration while researchers measured electrical signals from a leg muscle. The goal was to understand how vibration ch…
Phase: NA • Sponsor: Istanbul Physical Medicine Rehabilitation Training and Research Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:00 UTC
-
Tiny study hopes to simplify muscle testing for rare muscle disease
Knowledge-focused CompletedThis study looked at a new way to measure muscle function in people with inflammatory myopathies (diseases that cause muscle weakness). Researchers compared a simple test called the Myositis Functional Index-3 with advanced computerised muscle testing. They also tested whether a …
Phase: NA • Sponsor: Federal University of Espirito Santo • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:00 UTC
-
Could a seed protein stop oral cancer? early study hints at promise
Knowledge-focused CompletedThis early-phase study looked at whether a protein from the Maackia amurensis seed (MASL) can target a receptor called podoplanin found on oral cancer and precancerous cells. Researchers measured how much of this receptor was present in tissue samples from 18 adults with suspicio…
Phase: EARLY_PHASE1 • Sponsor: Rowan University • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:03 UTC
-
Skin biopsy study aims to unlock Vitiligo's repigmentation mystery
Knowledge-focused CompletedThis study compares skin samples from 20 people with vitiligo and 20 healthy volunteers to understand why certain body areas (like the face) repigment well while others (like hands and feet) do not. Researchers will analyze gene activity in skin from five different body sites. Th…
Phase: NA • Sponsor: Centre Hospitalier Universitaire de Nice • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:03 UTC
-
Prenatal diet linked to baby eczema, new study finds
Knowledge-focused CompletedThis study followed 487 pregnant women in Shanghai to see if key nutrients like folate and vitamin D affect the chance of their baby developing eczema (atopic dermatitis) by 6 months old. Researchers measured nutrient levels in the mothers' blood and checked babies for eczema usi…
Sponsor: Children's Hospital of Fudan University • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:02 UTC
-
Eczema mystery: could skin fungi be the culprit on your face and neck?
Knowledge-focused CompletedThis study looked at the types of fungi living on the head and neck skin of 30 adults with eczema (atopic dermatitis) compared to healthy volunteers. The goal was to understand if differences in the fungal community are linked to eczema in these areas. Researchers used advanced l…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:00 UTC
-
Dupilumab in pregnancy: no major safety signals found
Knowledge-focused CompletedThis study looked at whether the drug dupilumab, used for eczema or asthma, is safe during pregnancy. Researchers compared 581 pregnant women who took dupilumab with those who did not. They tracked birth defects, miscarriages, and infant health up to one year old to see if the dr…
Sponsor: Regeneron Pharmaceuticals • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:11 UTC
-
Real-World study checks eczema drug safety in teens
Knowledge-focused CompletedThis study looked at the safety and effectiveness of the eczema drug upadacitinib in teenagers aged 12 to under 18 in Japan. About 170 teens who were already prescribed the drug by their doctor took part. Researchers collected data from regular clinic visits and questionnaires ov…
Sponsor: AbbVie • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:08 UTC
-
HIIT vs MIIT: which workout wins for athlete performance?
Knowledge-focused CompletedThis study compared High-Intensity Interval Training (HIIT) and Medium-Intensity Interval Training (MIIT) in 36 athletes aged 20-30. Participants trained three times a week for six weeks. Researchers measured changes in heart-lung fitness, strength, and agility to see which metho…
Phase: NA • Sponsor: Riphah International University • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:07 UTC
-
AI boosts doctor accuracy for rare skin diseases in new study
Knowledge-focused CompletedThis study tested whether an artificial intelligence (AI) tool could help doctors diagnose rare and tricky skin conditions like generalized pustular psoriasis (GPP). Fifteen doctors, including both general practitioners and dermatologists, looked at 100 skin images. They first ga…
Sponsor: AI Labs Group S.L • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:07 UTC
-
Laser vs scalpel: which biopsy hurts less for mouth disease?
Knowledge-focused CompletedThis study tested whether using a laser for oral biopsies causes less pain and heals better than the standard punch scalpel in people with oral lichen planus. 112 adults were randomly assigned to one of the two methods. Researchers measured wound healing and discomfort after the …
Phase: NA • Sponsor: Catholic University of the Sacred Heart • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:06 UTC
-
New tool helps patients and doctors choose psoriasis treatments together
Knowledge-focused CompletedThis study aimed to create and test a decision aid for people with psoriasis or psoriatic arthritis who are starting or switching treatments. Researchers worked with 37 patients and their doctors to design a tool that supports shared decision-making. The goal was to help patients…
Phase: NA • Sponsor: University of Pennsylvania • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:06 UTC
-
Thousands tracked in psoriasis drug safety registry
Knowledge-focused CompletedThis study followed over 2,300 adults with moderate to severe plaque psoriasis to see how safe and effective secukinumab is in everyday medical practice. Researchers recorded side effects and how well the drug cleared skin symptoms. The goal was to gather real-world evidence, not…
Sponsor: Novartis Pharmaceuticals • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:06 UTC
-
Saliva secrets: could proteins tell two mouth diseases apart?
Knowledge-focused CompletedThis study looked at saliva from 21 people: some with oral lichen planus, some with oral leukoplakia, and some healthy. The goal was to see if proteins in saliva are different between these groups. Researchers hope these protein differences could one day help doctors tell these t…
Sponsor: Kocaeli University • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:06 UTC
-
Scientists test designer immune molecules in autoimmune diseases
Knowledge-focused CompletedThis study looked at whether specially engineered versions of a natural immune protein (IL-2) can selectively boost regulatory T cells, which help calm the immune system. Researchers took blood samples from 67 people with various autoimmune or inflammatory conditions and tested t…
Phase: NA • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:05 UTC
-
Coaching eases tough move to adult rheumatology care
Knowledge-focused CompletedThis study tested whether coaching sessions are practical for young people with rheumatic diseases moving from pediatric to adult care. 26 participants received up to 8 coaching sessions covering self-advocacy, medication management, and future planning. The main goal was to see …
Phase: NA • Sponsor: McMaster University • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:04 UTC
-
Japanese registry sheds light on how palmoplantar pustulosis is treated
Knowledge-focused CompletedThis completed registry study in Japan looked at how doctors treat palmoplantar pustulosis (PPP), a skin condition causing pus-filled blisters on hands and feet. Researchers collected data from 276 patients' medical records and clinic visits to understand which treatments are use…
Sponsor: Janssen Pharmaceutical K.K. • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:03 UTC
-
Eczema study uncovers potential new treatment path
Knowledge-focused CompletedThis study looked at a specific immune pathway (PGE2/IL22/IL17) in people with eczema to see if it plays a role in the disease. Researchers collected skin and blood samples from 38 participants, including those with eczema, psoriasis, and healthy volunteers. The goal was to ident…
Sponsor: NHS Lothian • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:03 UTC
-
Pemphigus study digs into hidden emotional struggles
Knowledge-focused CompletedThis study looked at 48 adults with pemphigus, a rare blistering skin disease, to understand what makes them feel vulnerable during their illness. Researchers used interviews and questionnaires to explore factors like misdiagnosis, differences in how patients and doctors see dise…
Phase: NA • Sponsor: University Hospital, Rouen • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:02 UTC
-
Does a potent steroid cream cause fluid retention? new study investigates
Knowledge-focused CompletedThis study measured fluid retention in 30 people with bullous pemphigoid who were treated with a strong steroid cream (clobetasol propionate). Researchers used bioimpedance to track changes in body water over 30 days. The goal was to understand if the cream causes fluid buildup a…
Phase: PHASE4 • Sponsor: University Hospital, Rouen • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:02 UTC
-
Breath test breakthrough: scientists read RNA in exhaled air
Knowledge-focused CompletedThis pilot study tested whether it is possible to collect and analyze small RNA molecules from a person's breath. Researchers took breath samples from 25 volunteers (healthy people and a few with lung disease) at rest and after intense exercise. They successfully extracted and se…
Sponsor: Medical University of Bialystok • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:02 UTC
-
Scientists probe gene activity in rare swelling disorder
Knowledge-focused CompletedThis study looked at gene activity in immune cells from 30 people with hereditary angioedema and healthy volunteers. The goal was to see if certain receptors on monocytes are linked to inflammation and blood vessel problems. No treatment was given; the study was purely observatio…
Phase: NA • Sponsor: University Hospital, Rouen • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:02 UTC
-
Flashing glasses may boost volleyball performance, study finds
Knowledge-focused CompletedThis study tested whether wearing special stroboscopic glasses during volleyball drills could improve how players' brains and bodies react. 42 female volleyball players aged 10-16, from beginners to elite, took part. They did 8 weeks of extra drills with or without the glasses. R…
Phase: NA • Sponsor: Bozok University • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:02 UTC
-
Parents test new app to track baby eczema and gut health
Knowledge-focused CompletedThis completed study looked at how well parents of infants with early eczema and parents of healthy infants could use a mobile-friendly platform called OneBiome. The platform gives reports on the baby's gut microbiome and eating patterns. Researchers wanted to see if parents foun…
Sponsor: Danone Asia Pacific Holdings Pte, Ltd. • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:02 UTC
-
Study reveals: athletes and couch potatoes worry differently about AI
Knowledge-focused CompletedThis completed study looked at how much anxiety people feel about artificial intelligence, comparing athletes (who exercise regularly) with sedentary individuals (who don't). Over 660 participants filled out a questionnaire measuring their AI-related worries. The goal was to see …
Sponsor: KTO Karatay University • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:01 UTC
-
Psoriasis skin study completed: scientists examine immune cells and proteins
Knowledge-focused CompletedThis completed study looked at skin samples from 40 people with psoriasis to understand how certain immune cells (CD4+ T cells) and a protein called S100A7 behave in psoriatic skin. Researchers used special staining techniques to measure these components. The goal was to learn mo…
Phase: NA • Sponsor: Sohag University • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:13 UTC
-
Eczema drug delivery showdown: autoinjector vs vial
Knowledge-focused CompletedThis study tested how well the body absorbs rocatinlimab, a drug for atopic dermatitis (eczema), when given through an autoinjector pen compared to a traditional vial and syringe. It involved 231 healthy adults aged 18-60. The goal was to see if the autoinjector delivers the drug…
Phase: PHASE1 • Sponsor: Amgen • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:13 UTC
-
Jump Training's hidden impact on athlete muscles revealed
Knowledge-focused CompletedThis study looked at whether lower-body plyometric training changes levels of certain muscle damage markers in the blood of female college volleyball players. Sixty players were split into two groups: one did plyometric exercises twice a week for 8 weeks, while the other stuck to…
Phase: NA • Sponsor: Cairo University • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:13 UTC
-
Tiny needles tap skin fluid for clues about eczema
Knowledge-focused CompletedThis study tested a new way to collect fluid from the skin using a tiny microneedle patch. Researchers compared samples from 20 healthy volunteers and people with eczema (atopic dermatitis) to see how much fluid could be collected and how well it was tolerated. The goal was to le…
Sponsor: Incyte Corporation • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:11 UTC
-
AI could cut skin specialist wait times, study hints
Knowledge-focused CompletedThis study tested an artificial intelligence algorithm designed to help primary care doctors decide whether a patient with a skin condition really needs to see a dermatologist. Researchers enrolled 200 adults with skin problems and had their doctors take photos of the affected ar…
Sponsor: AI Labs Group S.L • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:11 UTC
-
Real-World data on HAE attack treatment collected in completed study
Knowledge-focused CompletedThis study followed 88 people with hereditary angioedema (HAE) types I or II who already use icatibant for sudden attacks. Participants filled out diaries for 48 hours after each attack to report symptom changes, severity, and anxiety levels. The goal was to gather real-world inf…
Sponsor: KalVista Pharmaceuticals, Ltd. • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:10 UTC
-
New study reveals how fatigue impacts psoriasis and arthritis patients
Knowledge-focused CompletedThis study looked at fatigue in 33 adults with psoriatic arthritis or psoriasis. Researchers used questionnaires to measure tiredness and see how it relates to disease severity and treatments. The goal was to better understand fatigue and its impact on quality of life.
Phase: NA • Sponsor: Centre Hospitalier Henri Duffaut - Avignon • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:09 UTC
-
New eczema drug candidate tested in healthy chinese volunteers
Knowledge-focused CompletedThis early-phase study tested a single dose of the experimental drug rocatinlimab in 20 healthy Chinese adults. The main goal was to see how the drug moves through the body and whether it is safe. This is a first step toward possibly using the drug to treat atopic dermatitis (ecz…
Phase: PHASE1 • Sponsor: Amgen • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:08 UTC
-
Beans and lentils: the secret weapon for competitive swimmers?
Knowledge-focused CompletedThis study looked at whether adding more legumes (like beans, lentils, and chickpeas) to a Mediterranean diet could improve hydration, heart rate balance, and swimming performance in competitive swimmers. Thirty-nine adolescent and young adult swimmers were split into groups base…
Phase: NA • Sponsor: San Raffaele Telematic University • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:08 UTC
-
Korfball athletes test new training to boost strength and reduce injury risk
Knowledge-focused CompletedThis study looked at how a 10-week complex training program—mixing heavy weights with explosive jumps—affects the physical fitness, balance, and shooting of Chinese national korfball players. Twenty-four athletes completed the program, and researchers measured changes in strength…
Phase: NA • Sponsor: Universiti Sains Malaysia • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:07 UTC
-
Footballers get mega vitamin d dose in exercise study
Knowledge-focused CompletedThis pilot study gave 20 professional football players either a single high dose of vitamin D or a placebo before a match. Researchers measured how vitamin D levels changed in their blood. The goal was to see how exercise affects vitamin D metabolism, not to treat any disease.
Phase: NA • Sponsor: Wroclaw University of Health and Sport Sciences • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:07 UTC
-
Staph bacteria may worsen eczema and trigger dangerous infections
Knowledge-focused CompletedThis study looked at how staphylococcus bacteria on the skin affect inflammation and immune responses in people with moderate to severe atopic dermatitis (eczema). Researchers took skin biopsies and blood samples from 41 adults to measure bacterial toxins and immune cell activity…
Phase: NA • Sponsor: Poitiers University Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:07 UTC
-
Scientists compare core endurance and pelvis in athletes vs. couch potatoes
Knowledge-focused CompletedThis study looked at 114 healthy adults (athletes and non-athletes) to see if core muscle endurance is linked to pelvic width and movement. Participants did simple holding exercises like wall sits and planks while researchers measured their pelvis. The goal was to understand how …
Sponsor: Gazi University • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:07 UTC
-
Healthy volunteers test new injection method for eczema drug
Knowledge-focused CompletedThis study tested how the body absorbs rocatinlimab, a potential eczema treatment, when given through a vial versus a prefilled syringe. 240 healthy adults received a single dose to compare the two methods. The goal was to see if the syringe works as well as the vial, not to trea…
Phase: PHASE1 • Sponsor: Amgen • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:06 UTC
-
Scientists probe blood immune clues in common Dandruff-Like skin condition
Knowledge-focused CompletedThis study looked at immune cells in the blood of 15 adults with seborrheic dermatitis (a chronic, flaky skin condition) and 15 healthy people. Researchers measured different types of immune cells and chemicals to see if there are differences between the two groups. They also ask…
Sponsor: San Gallicano Dermatological Institute IRCCS • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:06 UTC
-
Eczema drug interaction study: will rocatinlimab change how other meds work?
Knowledge-focused CompletedThis early-phase study looked at how rocatinlimab, an experimental drug for eczema, affects the way the body processes several common medications (caffeine, metoprolol, midazolam, warfarin, omeprazole). 21 adults with moderate to severe eczema took these drugs with and without ro…
Phase: EARLY_PHASE1 • Sponsor: Amgen • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:06 UTC
-
Real-world study tracks xolair dose bumps for stubborn hives
Knowledge-focused CompletedThis study looked at how often doctors increase the dose or give Xolair more frequently for people with chronic hives. Researchers followed 163 adults for 3 months to see how many needed a stronger treatment plan. The goal was to understand real-world use, not to test a new drug.
Sponsor: University Hospital, Lille • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:06 UTC
-
Tiny skin tests reveal psoriasis nerve clues
Knowledge-focused CompletedThis study looked at how skin blood flow and nerve sensitivity differ in psoriasis plaques compared to healthy skin. Twenty adults with psoriasis on their back received mild electrical currents to deliver vasodilators (acetylcholine, sodium nitroprussiate, or plain water) into bo…
Phase: NA • Sponsor: Hospices Civils de Lyon • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:05 UTC
-
Pandemic's hidden toll: skin allergies surge among healthcare workers
Knowledge-focused CompletedThis study examined how the COVID-19 pandemic impacted skin allergy visits among healthcare workers. Researchers analyzed records from 341 healthcare workers who visited skin clinics before and after the pandemic. The goal was to understand if increased use of masks, gloves, and …
Sponsor: Centre Hospitalier Intercommunal Creteil • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:04 UTC
-
Are pro gamers hurting? new study investigates pain and sleep in E-Athletes
Knowledge-focused CompletedThis study examined 86 professional e-athletes aged 18-35 to understand what factors are linked to pain, fatigue, and poor sleep quality. Researchers assessed pain severity, fatigue levels, sleep quality, and physical activity. The goal is to identify health risks in esports and …
Sponsor: Bandırma Onyedi Eylül University • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:04 UTC
-
New biologic LP-003 takes first step in human safety trial
Knowledge-focused CompletedThis study tested the safety and tolerability of a new biologic drug called LP-003 in 60 healthy volunteers. The drug is being developed for chronic spontaneous urticaria (long-lasting hives). The trial gave single or multiple doses of LP-003 or a placebo by IV to see how the bod…
Phase: PHASE1 • Sponsor: Longbio Pharma • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:03 UTC
-
Skin deep: new study probes hidden signals in hidradenitis
Knowledge-focused CompletedThis study examined skin samples from 15 people with hidradenitis suppurativa (HS) and 15 healthy volunteers to measure certain genes and proteins linked to inflammation. The goal was to better understand what causes HS and find possible markers of disease severity. No treatment …
Sponsor: Trakya University • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:03 UTC
-
Psoriasis drug interaction study completed: what Hemay005 does to the body
Knowledge-focused CompletedThis study involved 20 adults with psoriasis to see how Hemay005 tablets affect the way the body processes another drug called midazolam. Researchers also checked for heart rhythm changes and measured inflammation markers. The goal was to gather safety and drug interaction data, …
Phase: PHASE1 • Sponsor: Ganzhou Hemay Pharmaceutical Co., Ltd • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:01 UTC
-
Kidney function may change how psoriasis drug works
Knowledge-focused CompletedThis completed Phase 1 study tested how the psoriasis drug Hemay005 is processed by the body in people with mild or moderate kidney impairment compared to those with normal kidneys. 26 adults took a single dose, and researchers measured drug levels in the blood to see if kidney f…
Phase: PHASE1 • Sponsor: Ganzhou Hemay Pharmaceutical Co., Ltd • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:01 UTC
-
Vitiligo linked to higher risk of depression and anxiety in major study
Knowledge-focused CompletedThis study looked at over 36,000 adults in the UK to see if people with vitiligo are more likely to have mental health problems like depression, anxiety, or self-harm compared to those without vitiligo. Researchers used medical records to compare risks and also checked if these r…
Sponsor: Momentum Data • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:01 UTC
-
Can loud music throw off an Athlete's balance? VR study investigates
Knowledge-focused CompletedThis study looked at how different music volumes affect balance in athletes. 48 healthy athletes listened to soft, medium, and loud music while standing on a virtual reality balance system. The goal was to see if sound intensity changes how well they can keep steady.
Phase: NA • Sponsor: Hanifi Korkmaz • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:01 UTC
-
Wildfire smoke may cloud your thinking, new study suggests
Knowledge-focused CompletedThis study looked at how breathing in simulated wildfire smoke for just one hour affects healthy adults. Researchers measured a blood marker called p-tau, which is linked to memory problems, and tested thinking skills before and after exposure. The goal was to see if short-term s…
Phase: NA • Sponsor: Rutgers, The State University of New Jersey • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:01 UTC
-
New study reveals how long patients stay on secukinumab for skin and joint conditions
Knowledge-focused CompletedThis completed study followed 127 adults with moderate to severe plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, or non-radiographic axial spondyloarthritis who were already taking or starting secukinumab. Researchers observed them for two years to see how long the…
Sponsor: Novartis Pharmaceuticals • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:00 UTC
-
New turkish scale helps athletes measure back pain disability
Knowledge-focused CompletedThis study translated an English questionnaire into Turkish to help athletes with low back pain measure how their pain affects sports and daily activities. 120 Turkish athletes with low back pain filled out three questionnaires. The goal was to make sure the Turkish version is ac…
Sponsor: Medipol University • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:59 UTC
-
Thirst-Guided hydration studied in Ultra-Trail runners
Knowledge-focused CompletedThis study followed 198 runners in the 2015 Ultra-Trail Mont-Blanc to see if drinking only when thirsty ("at thirst") keeps blood sodium levels more stable compared to other drinking plans. The goal is to understand how hydration affects health during extreme endurance events. Re…
Phase: NA • Sponsor: Centre Hospitalier Universitaire de Nīmes • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:58 UTC
-
Could a simple drink before pregnancy shape your child's future health?
Knowledge-focused CompletedThis study followed 461 children whose mothers took a special nutritional drink before and during pregnancy. Researchers want to understand how parents' diet, lifestyle, and metabolism influence child growth, thinking skills, and overall well-being. The goal is to identify factor…
Phase: NA • Sponsor: University of Southampton • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:58 UTC
-
New study reveals hidden toll of vitiligo on chinese patients
Knowledge-focused CompletedThis study looked at how vitiligo affects people in China, including their treatments and daily life. Researchers observed 100 patients to measure the disease's impact on their skin and quality of life. The goal was to better understand the real-world burden of this condition.
Sponsor: AbbVie • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:57 UTC
-
New drug absorption study aims to improve future eczema treatments
Knowledge-focused CompletedThis study looked at how an experimental medicine called PF-08049820 moves through the body when taken in different forms (fast-release and slow-release tablets) and with or without food. Twelve healthy adults each tried five versions of the medicine, with blood samples taken for…
Phase: PHASE1 • Sponsor: Pfizer • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:57 UTC
-
Eczema drug Dupilumab's skin gene secrets revealed in small study
Knowledge-focused CompletedThis study looked at how the eczema drug dupilumab (Dupixent) affects immune cells and genes in the skin. Seventeen adults with moderate-to-severe eczema took the drug, and researchers measured changes in skin samples over 12 weeks. The goal was to understand the biological effec…
Phase: PHASE4 • Sponsor: University of California, San Francisco • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:57 UTC
-
Eczema drug may weaken vaccine protection, study finds
Knowledge-focused CompletedThis study looked at whether rocatinlimab, a drug for moderate-to-severe eczema, changes how well vaccines work. About 221 adults with eczema received either the drug or a placebo, then got tetanus and meningococcal vaccines. The goal was to see if the drug lowers the body's abil…
Phase: PHASE3 • Sponsor: Amgen • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:56 UTC